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A B S T R A C T
Background
Poor adherence to therapy is a significant healthcare issue, particularly in patients with chronic disease such as open-angle glaucoma.
Treatment failure may necessitate unwarranted changes of medications, increased healthcare expenditure and risk to the patient if
surgical intervention is required. Simplifying eye drop regimes, providing adequate information, teaching drop instillation technique
and ongoing support according to the patient need may have a positive effect on improving adherence.
Objectives
To summarise the effects of interventions for improving adherence to ocular hypotensive therapy in people with ocular hypertension
(OHT) or glaucoma.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 6),
MEDLINE (June 1946 to June 2012), EMBASE (June 1980 to June 2012), Cumulative Index to Nursing and AlliedHealth Literature
(CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June 2012), PsycEXTRA (1908 to June 2012), Web of Science (1970 to
June 2012), ZETOC (1993 to June 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/),
the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO
International Clinical Trials Registry Platform (ICTRP) (www.who.int/ ictrp/search/en).We did not use any date or language restrictions
in the electronic searches for trials. The electronic databases were last searched on 26 June 2012. We did not search theNational Research
Register (NNR) as this resource has now been now archived. We contacted pharmaceutical manufacturers to request unpublished data
and searched conference proceedings for the Association for Research in Vision and Ophthalmology (ARVO), and the Annual Congress
for the Royal College of Ophthalmologists (RCO).
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs that compared interventions to improve adherence to ocular hy-
potensive therapy for patients with OHT or glaucoma.
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Data collection and analysis
At least two authors independently assessed the search results for eligibility and extracted data for included trials onto specifically
designed forms. We did not pool data due to clinical and methodological heterogeneity.
Main results
Sixteen trials (1565 participants) met the inclusion criteria. Seven studies investigated some form of patient education. In six of
these studies this education was combined with other behavioural change interventions including tailoring daily routines to promote
adherence to eye drops. Eight studies compared different drug regimens (one of these trials also compared open andmaskedmonitoring)
and one study investigated a reminder device. The studies were of variable quality and some were at considerable risk of bias; in general,
the length of follow-up was short at less than six months with only two studies following up to 12 months. Different interventions
and outcomes were reported and so it was not possible to produce an overall estimate of effect. There was some evidence from three
studies that education combined with personalised interventions, that is, more complex interventions, improved adherence to ocular
hypotensive therapy. There was less information on other outcomes such as persistence and intraocular pressure, and no information
on visual field defects, quality of life and cost. There was weak evidence as to whether people on simpler drug regimens were more
likely to adhere and persist with their ocular hypotensive therapy. A particular problem was the interpretation of cross-over studies,
which in general were not reported correctly. One study investigated a reminder device and monitoring but the study was small and
inconclusive.
Authors’ conclusions
Although complex interventions consisting of patient education combined with personalised behavioural change interventions, in-
cluding tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medication, overall there
is insufficient evidence to recommend a particular intervention. The interventions varied between studies and none of the included
studies reported on the cost of the intervention. Simplified drug regimens also could be of benefit but again the current published
studies do not provide conclusive evidence. Future studies should follow up for at least one year, and could benefit from standardised
outcomes.
P L A I N L A N G U A G E S U M M A R Y
Interventions for helping people use eye drops as prescribed for raised eye pressure or glaucoma
A large number of people do not use eye drops as prescribed. Glaucoma is a slowly progressive eye disease, which can result in severe
vision loss. Drops prescribed for raised eye pressure or glaucoma are aimed at lowering the pressure to assist in reducing the rate of
progression, or preventing the conversion of raised eye pressure to glaucoma. It is important that these eye drops are used continually,
usually for life. Approximately one-third of people who are prescribed eye drops for the first time fail to continue collecting prescriptions
within the first year and even when patients collect prescriptions they do not always use the drops as frequently as they should. A
number of reasons are thought to be the cause, for example, forgetfulness, being prescribed a large number of medications, difficulties
instilling drops, lack of knowledge about glaucoma, a busy lifestyle and seeing no benefit.
This review is based on 16 studies (1565 participants) that tried out different methods to help people to use drops as prescribed. All
the studies took place in industrialised countries (Belgium, Denmark, France, Greece, Iceland, Japan, Sweden, Switzerland, UK and
USA) and recruited participants in outpatient clinics. The following interventions were included: simplifying drop routines, reminder
devices, automated telephone service, providing information about glaucoma and offering advice regarding day to day issues with eye
care. Those studies which combined the provision of information about glaucoma and eye drops with other interventions, such as
helping people to fit instillation of eye drops into their daily routine, appear to be more successful. Unfortunately, not all of these
studies were of high quality and, therefore, until more evidence is available we cannot recommend any particular method. Good quality
research is needed in this area in order to develop a better understanding of patients’ individual needs and to help us provide more
effective eye care services.
2Interventions for improving adherence to ocular hypotensive therapy (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Education and individualised care planning compared with standard care for improving adherence to ocular hypotensive therapy
Patient or population: people with glaucoma or ocular hypertension
Settings: outpatients
Intervention: education and individualised care planning
Comparison: standard care
Outcomes No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Adherence 902
(7)
⊕⊕©©
low1
3 studies found that people given
education and individualised care
planning were more adherent.
Substantial improvements in ad-
herence were observed in these
studies. 4 studies did not find a
difference, in these studies the
intervention was less detailed.
Different measures of adherence
meant it was difficult to estimate
overall treatment effect
Persistence 127
(1)
⊕⊕©©
low2
Only 1 trial reported this outcome
in which 17/127 patients discon-
tinued therapy (risk ratio for per-
sistence 1.14, 95% CI 0.99 to 1.
41)
Intraocular pressure 193
(2)
⊕⊕©©
low3
Only 2 trials reported this out-
come. One trial reported this at
12 and 24 months and found no
difference between the interven-
tion groups. 1 trial reported at 3
months follow-up which may be
too short a time period to observe
an effect on intraocular pressure
Visual field defects No data on this outcome
Quality of life No data on this outcome
Adverse effects No data on this outcome
Patient knowledge 390
(4)
⊕©©©
low4
In Gray 2011 intervention im-
proved patient knowledge (me-
dian knowledge score was 14
(range 2 to 18) for the interven-
tion group and 6 (range 0 to 17)
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for the control group (Mann-Whit-
ney P <0.001). 3 other studies
reported no differences in patient
knowledge between groups
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1We downgraded to low because (i) the majority of the trials were not masked , (ii) there was inconsistency in trial results.
2We downgraded to low because (i) only one trial, (ii) imprecision in the estimate.
3We downgraded to low because (i) only one trial measured at reasonable length of follow-up, (ii) no pooled estimate so not enough
numbers to detect moderate effects.
4We downgraded to low because (i) inconsistency in trial results, (ii) the majority of the trials were not masked.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
There are a number of terms that describe whethermedications are
taken as prescribed. Adherence has superseded the term compli-
ance and although synonymous with compliance, has fewer nega-
tive connotations and is intended to be non-judgemental (Haynes
1979; Horne 2006). Adherence will, therefore, be used through-
out the review.
A useful taxonomy for describing adherence to medication helps
to clarify the confusion surrounding the proliferation of ambigu-
ous terms on medication adherence. In this taxonomy, non-ad-
herence to medications is said to occur by late or non-initiation
of prescribed treatment, by sub-optimal implementation of the
regimen and by early discontinuation of therapy sometimes re-
ferred to as persistence (Vrijens 2012). Although persistence may
be achieved by the patient collecting all dispensed prescriptions,
it does not necessarily follow that the medication will be taken
as prescribed. Because adherence is difficult to measure, persis-
tence (which can be objectively measured) is often employed as
an outcome for studies investigating adherence (Wilensky 2006;
Yu 2005). Another term often confused with adherence is concor-
dance. Concordance describes an agreement reached after negoti-
ation between a patient and a healthcare professional that respects
the beliefs and wishes of the patient in determining whether, when
and how medicines are to be taken. Although reciprocal, this is an
alliance in which healthcare professionals recognise the primacy of
the patient’s decision about taking the recommended medications
(Royal Pharmaceutical Society of Great Britain 1997).
Concordance is not synonymous with compliance or adherence.
Concordance focuses on the consultation process rather than spe-
cific patient behaviour and has an underlying ethos of a shared ap-
proach to decision making (Weis 2003). The concept involves the
pooling of patients’ and health professionals’ beliefs, experiences
and expertise to arrive at mutually agreed goals (Bissell 2004). To
ensure completeness for this review, our search strategy will incor-
porate the above terms and any other terminology associated with
adherence.
Poor adherence most often leads to increased resource utilisation,
owing to a reduction in effectiveness and associated increase in the
risk of therapeutic failure (Urquhart 1999). Treatment failure may
necessitate more frequent hospital appointments and diagnostic
tests, unwarranted increases in doses or changes of medications,
waste of unfinished pharmaceutical supplies, increased healthcare
expenditure and risk to the patient if subsequent surgical inter-
vention is required. Electronic monitoring devices are considered
the gold standard for measuring adherence because they are an
objective measure of behaviour but experimenter’s bias may be a
limitation. A systematic review of seven studies using this method
reports that there are a sizeable group of 20% or less of patients
who are defined as non-adherent (Reardon 2011). Other studies
also identify from electronic monitoring that patients’ behaviour
can be grouped into such categories as fully adherent, non-per-
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sistent, taking regular breaks/dosing holidays or erratic frequent
missing of doses (Ajit 2010; Herman 2010). Research from a sys-
tematic review of medical chart reviews (six studies) indicates that
at one year 67% (range 62% to 78%) of patients remained persis-
tent with their anti-glaucoma medication (Reardon 2011).
In chronic, asymptomatic diseases such as open-angle glaucoma
(OAG), adherence is a particular issue. The treatment for glau-
coma aims to prevent disease progression, yet provides no sub-
jective improvement in well-being, and may even cause ocular or
systemic side effects, or both (Diggory 1995).
In a systematic review by Olthoff 2005 non-adherence ranged
from 4.6% to 80% across 34 studies. A more recent review found
the prevalence of non-adherence to glaucoma treatment to range
from 23% to 60% over 12 months (Lu 2010). A variety of defi-
nitions for non-adherence and assessment methods were found to
be in use. This emphasises our poor understanding and the poor
classification of adherence.
Description of the condition
Glaucoma is an optic neuropathy characterised by an acquired loss
of retinal ganglion cells, atrophy of the optic nerve and loss of vi-
sual field (Maier 2005). Increased intraocular pressure (IOP) may
be present as in open-angle glaucoma (OAG) and angle-closure
glaucoma (ACG). Glaucomatous optic neuropathy and field loss
with normal IOP is known as normal tension glaucoma (NTG).
Elevated IOP in the absence of glaucomatous appearance of the
optic nerve head or visual field is known as ocular hypertension
(OHT). Intraocular pressure control (reduction and control of
fluctuations) has a role in preventing the onset (for patients with
OHT) and reducing the rate of progression of glaucoma (Heijl
2002). It is routinely monitored in clinical practice in conjunction
with other risk factors such as the structural appearance of the
optic nerve head and visual field status (Spry 2005).
Glaucoma is the leading cause of irreversible blindness worldwide.
A review of 34 studies involving patients with OAG and ACG
estimated the prevalence of glaucoma to be 60.5 million by 2010
(74% with OAG) rising to nearly 80 million by 2020; with an
ageing population accounting for a large proportion of this rise
(Quigley 2006). Ameta-analysis confirmedprevious estimates that
black populations had the highest prevalence of OAG at 4.2%,
ranging from 2.9% at the age of 40 years to 16.9% at 80+ years
(Rudnicka 2006). The prevalence for white populationswas 2.1%,
ranging from 0.4% at age 40 years to 6.6% at 80+ years, and for
Asian populations was 1.4%, ranging from 0.6% to 3.8% for the
same age range.
In its early stages, glaucoma is asymptomatic and approximately
one in two people with the disease may be undiagnosed (Quigley
2006). In a north London-based cross-sectional survey, 74% of
those found to have a definite diagnosis of glaucoma and 84% of
suspected glaucoma cases were not known to an eye care service
(Reidy 1998). People at risk of developing glaucoma are more
likely to present late if they have no family history of glaucoma or
do not visit an optometrist regularly (Fraser 1999). Themajority of
cases are detected during routine eye examination and, therefore,
increasing public awareness of the disease may be valuable for
early detection. Patients newly diagnosed with OHT or glaucoma
should have the opportunity tomake informed choices about their
long-term care. Deokule 2004 found only 52% of patients could
name their medication or frequency of instillation correctly. An
Australian study reports that of 200 patients with glaucoma, 32%
could not state their prescribed therapeutic regimen and that those
with three or more prescribed eye drops were five times more
likely not to know their medication (O’Hare 2009). Providing
adequate information, advice and ongoing support according to
patient need may have a positive effect on improving adherence.
Description of the intervention
Treatment of patients with OHT or glaucoma aims to prevent vi-
sual disability and preserve overall well-being (Burr 2012). Ther-
apy focuses on lowering IOP levels in an attempt to slow the rate
of disease progression or prevent the conversion of OHT to glau-
coma within a person’s lifetime (NICE 2009).
First-line treatment usually consists of mono-therapy, commenc-
ing with an uncomplicated regime of one drop per day. Even
the simplest regimes are subject to poor persistence rates, as
Vanelli 2009 found that it was medication-naive patients with pre-
scribed non-oral medicines (diabetes mellitus, insulin; glaucoma,
eye drops; asthma, inhalers) who were most at risk of discontin-
uation in the first 30 days of therapy compared with those who
were more experienced. This supports the early provision of pa-
tient education and support in an attempt to prevent early discon-
tinuation (Lunnela 2010). For many patients, multiple therapy is
required and this has led to the introduction of fixed-combina-
tion drops (two active ingredients in a single drop) for patients
requiring more than one preparation. The aim of fixed combi-
nation drops is to enable a more complex dosing regimen while
allowing the patient to benefit from a once only dose which may
improve adherence (Brown 1997). The previous version of our
review (Gray 2009) shows that there were a few studies which have
attempted to investigate this issue and, unfortunately, there was
insufficient evidence to confirm this claim.
How the intervention might work
Although complicated regimes do appear to affect adherence, there
is no evidence to date that indicates that there are any determi-
nants, such as age, race or level of education, that can predict
accurately potential patients who will not adhere. However, pre-
vious studies have found numerous patient-identified barriers to
adherence with anti-glaucoma medication, such as communica-
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tion difficulties between patient and physician, lack of knowledge
about glaucoma and the purpose of eye drops, forgetfulness, lack
of motivation, living alone, poor dexterity, a busy lifestyle and see-
ing no benefit (Granstrom 1982; Kholdebarin 2008; Lacey 2009;
Patel 1995; Schwartz 2008; Taylor 2002; Tsai 2003). These fac-
tors would seem to be amenable to interventions.
Why it is important to do this review
A previous Cochrane review synthesised the evidence relating to
adherence to a range of medications including oral and inhaled
drugs (Haynes 2008). Topical eye drops, however, were not in-
cluded. Olthoff 2005 published a systematic review relating to
poor adherence with ocular hypotensive treatment. This review
raised a number of interesting issues and did conclude that poor
adherence is a considerable concern. The authors suggested that
future research should take a more objective approach of measur-
ing adherence by means of medication monitors. Olthoff 2005
excluded drug trials on the basis that drug use under everyday cir-
cumstances may differ completely from the situation in a clinical
trial. We are aware of this, however, we believe drug studies should
be included. Studies that compare adherence rates for patients on
different drug regimes, such as daily combination drops versus
twice or three times daily mono-therapy, may prove to be benefi-
cial in informing future prescribing practices. Olthoff 2005 also
excluded studies if they reported involuntary non-adherence, e.g.
due to co-morbidity. Again, the authors of this review believe that
such trials are important. If a patient is unable to adhere to a pre-
scribed regime due to a co-existing condition such as Alzheimer’s
disease, this has implications for future service provision. This is an
update of our original Cochrane review published in 2009 (Gray
2009).
O B J E C T I V E S
To summarise the effects of interventions for improving adherence
to ocular hypotensive therapy in people with OHT or glaucoma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi RCTs
that compared interventions to improve adherence to ocular hy-
potensive therapy.
Types of participants
We included patients with a clinical diagnosis of glaucoma or
OHTwhowere prescribed ocular hypotensive therapy. There were
no age or gender limitations.
Types of interventions
We included any intervention that aimed to improve adherence
to ocular hypotensive therapy versus other interventions or usual
care. There were no restrictions on the type of ocular hypotensive
medications used. Studies included were likely to match one of
the following four comparisons:
1. Usual care versus adherence intervention and usual care.
2. Usual care versus adherence intervention alone.
3. Usual care and adherence intervention versus usual care and
an alternative adherence intervention.
4. Adherence intervention versus an alternative adherence
intervention.
Interventions may include, but are not exclusive to, the following:
• Patient education programmes.
• Verbal and written information.
• Follow-up support; telephone or postal reminders to collect
prescriptions and/or medication reminder charts.
• Rescheduling of eye drop therapy; simplification of dosing,
e.g. reducing the number of drops per day or tailoring regimes to
daily activities.
• Eye drop instillation training.
• Identification of adherence barriers and individualised
adherence plan.
Types of outcome measures
A gold standard for measuring adherence to glaucoma therapy
does not exist; methods vary greatly. This review incorporated any
measure for a study that met the inclusion criteria.
Primary outcomes
• Adherence to therapy measured as defined in each study;
including, but not limited to patient interviews, questionnaires,
patient diaries or electronic monitoring devices. This includes
dichotomous (success/failure), nominal (reasons for non/poor
adherence) and discrete data (proportions of missed doses over a
specific time period).
• Persistence with therapy measured by repeat prescriptions
(prescription refill) or dispensing counts, or both. This includes
dichotomous (success/failure) and discrete data (proportions of
uncollected prescriptions over a specific time period).
Secondary outcomes
• Intraocular pressure reduction measured via tonometry.
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• Progression of optic nerve head damage as defined by each
study.
• Progressive visual field loss as defined by each study.
• Quality of life
◦ We collected quality of life data where available and
where reported in association with adherence outcomes. Many
recognised tools are available, such as the MOS SF36 (Iester
2002), IPQ-R (Moss-Morris 2002) or VFQ-25 (Mangione
2001; Spaeth 2006). We included any validated quality of life
measure as reported in the trials.
• Adverse effects.
◦ Serious adverse events (fatal, life-threatening or require
hospitalisation).
◦ Adverse events that result in discontinuation of
treatment.
◦ Any other adverse events.
• Patients’ knowledge of glaucoma and its treatment.
• Costs.
Secondary outcome measures may involve the analysis of both
continuous and ordinal data.
Follow-up
Studies measuring adherence and persistence may vary. We have
included all studies meeting the criteria and categorised as follows:
• Short-term = < six months.
• Medium-term = six months to < one year.
• Long-term = ≥ one year.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2012, Issue 6, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 26 June 2012), MED-
LINE (June 1946 to June 2012), EMBASE (June 1980 to June
2012), Cumulative Index to Nursing and AlliedHealth Literature
(CINAHL) (June 1937 to June 2012), PsycINFO (1806 to June
2012), PsycEXTRA (1908 to June 2012),Web of Science (1970 to
June 2012), ZETOC (1993 to June 2012), OpenGrey (System for
Information on Grey Literature in Europe) (www.opengrey.eu/),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or lan-
guage restrictions in the electronic searches for trials. The elec-
tronic databases were last searched on 26 June 2012. We did not
search the National Research Register (NNR) as this resource has
now been now archived.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
CINAHL (Appendix 4), PsycINFO and PsycEXTRA (Appendix
5), Web of Science (Appendix 6), ZETOC (Appendix 7), Open-
Grey (Appendix 8), mRCT (Appendix 9), ClinicalTrials.gov
(Appendix 10) and the ICTRP (Appendix 11).
Searching other resources
We searched reference lists of identified trial reports to find ad-
ditional trials. We contacted primary investigators of identified
trials for details of additional trials. We also contacted pharma-
ceutical manufacturers of ocular hypotensive medications such as
Pfizer, Allergan, Alcon and Merck Sharp and Dohme to request
unpublished data that they were willing to release. We searched
the following conference proceedings for relevant abstracts both
electronically and by hand:
• Annual Meeting for the Association for Research in Vision
and Ophthalmology (ARVO) (2000 to 2008).
• Annual Congress for the Royal College of
Ophthalmologists (RCO) (1993 to 2008).
Data collection and analysis
Selection of studies
Two review authors working independently assessed the titles and
abstracts of all reports identified by the electronic and manual
searches as per ’Criteria for considering studies for this review’.
We obtained full reports for potentially eligible studies and for
those where we had insufficient information. Review authors were
not masked to names of the investigators, the institutions, jour-
nal of publication or results when making their assessments. In
cases where additional information was needed before a decision
could be made as to whether to include a trial, we attempted to
obtain this information by contacting investigators. We resolved
disagreements by consensus. We scrutinised results for duplicate
publications from the same data set. Details of excluded studies
have been retained and reasons for exclusion are documented in
the ’Characteristics of excluded studies’ table.
Data extraction and management
Extraction of study characteristics
At least two authors independently extracted the data from each
paper onto data extraction forms, designed specifically for the
review with guidance from the Cochrane Eyes and Vision Group.
We compared the extracted data for differences and discrepancies
were resolved by discussion.
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Data entry
Data was entered by one author into Review Manager 5 (RevMan
2012) (JE) and subsequently checked by another author (HW).
We approached the investigators for more information where data
were missing or difficult to determine from a trial report. We
designed study-specific data collection forms to capture data that
were not available from the published report.
Assessment of risk of bias in included studies
At least two authors independently assessed each study for risk of
bias, using the Cochrane Collaboration tool for assessing the risk
of bias as described in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Any disagree-
ments were resolved by discussion. We graded the following items
as low risk of bias, high risk of bias or unclear. We sought addi-
tional information from the authors of any study graded unclear.
1. Selection bias
We assessed the generation of the allocation sequence and alloca-
tion concealment.
2. Performance bias
We assessed the extent to which participant and care providers
were masked to the treatment group (blinding).
3. Detection bias
We assessed whether the outcome assessor was masked to the in-
tervention group.
4. Attrition bias
We recorded the amount of missing data and whether participants
were analysed in the groups towhich theywere originally randomly
allocated.
Assessment of heterogeneity
There was considerable clinical heterogeneity with respect to the
type of intervention and methodological heterogeneity with re-
spect to the measurement of outcomes so we did not perform any
meta-analyses.
Data synthesis
We did not conduct any data synthesis but tabulated data from
the different studies according to type of intervention.
Sensitivity analysis
We did not plan any sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
For the original review published in 2009, the electronic searches
identified a total of 1519 titles and abstracts. We did not find any
additional references by searching conference abstracts or by con-
tacting pharmaceutical companies. One further study was identi-
fied by someone who peer reviewed the review. We assessed the
titles and abstracts and agreed to look at 68 full-text papers. We
rejected 31 papers for lack of relevance to the review as many
were discussion papers and not studies. A further 27 were ex-
cluded for not meeting one or more inclusion criteria. Details of
these 27 studies are included in the ’Characteristics of excluded
studies’ table). Ten publications reporting 11 studies were con-
sidered eligible for inclusion. Three of these studies were ongo-
ing (see ’Characteristics of ongoing studies’ table). The remain-
ing eight completed studies (Laibovitz 1996; Laster 1996; Norell
1979; Sakai 2005; Schenker 1999; Sheppard 2003; Sverrisson
1999 USA; Sverrisson 1999 Europe) are compared in detail below
and further details can be found in the ’Characteristics of included
studies’ table.
An update search was run in June 2012 which retrieved a fur-
ther 654 records. The Trials Search Co-ordinator scanned the
search results and removed 476 records which were not relevant
to the scope of the review. We assessed the titles and abstracts
of the remaining 178 records for potential inclusion in the re-
view. We rejected 144 records. There were 13 reports of ongo-
ing studies (see ’Characteristics of ongoing studies’ for trial de-
tails). We obtained the full text of 21 publications for further as-
sessment. We included the following eight studies in the review:
Gray 2011; Hermann 2011a; Hermann 2011b; I-SIGHT; Muir
2012; Nakakura 2012; Okeke 2009; Ring 2011. We excluded the
following 13 studies: Gulkilik 2011; Inoue 2011; Inoue 2012;
Lorenz 2011; NCT00230763; NCT00262626; NCT00328835;
NCT00329095; NCT00348062; NCT01415401; Rolle 2012;
Rossi 2011; Sanchez-Pulgarin 2011.
Included studies
See Table 1 for a summary and individual tables for each included
trial (’Characteristics of included studies’).
We attempted to contact the study authors as a number of details
were missing for all included studies. Where contact was made
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we sent study-specific data collection forms via e-mail or post.
The information below is based on a combination of published
evidence and correspondence with authors. We have reviewed and
analysed Sverrisson 1999 USA and Sverrisson 1999 Europe as two
separate studies as the resultswere presented separately by the study
authors, although published within the same paper.
Study design
There were 14 RCTs and two quasi-RCTs (Ring 2011; Sakai
2005). Although not specified in the published article, Sakai 2005
conducted randomisation by rotation.
Five studies were cross-over studies (Laibovitz 1996; Laster 1996;
Schenker 1999; Sverrisson 1999 USA; Sverrisson 1999 Europe)
and the rest were parallel-group designs.
There were six multi-centre studies (I-SIGHT; Okeke 2009;
Nakakura 2012; Schenker 1999; Sverrisson 1999 Europe;
Sverrisson 1999 USA) and the rest were single-centre.
All the studies were conducted in industrialised countries (Bel-
gium, Denmark, France, Greece, Iceland, Japan, Sweden, Switzer-
land, UK and USA) and recruited participants in outpatient clin-
ics.
Four studies were commercially sponsored by Merck & Co
(Laibovitz 1996; Schenker 1999; Sverrisson 1999 USA; Sverrisson
1999 Europe), one study was part-funded by Pfizer (Gray 2011)
and one by Alcon (Okeke 2009), five studies were funded or
part-fundedby government or charitable organisations (I-SIGHT;
Laster 1996; Muir 2012; Okeke 2009; Ring 2011); and six did
not state funding sources or had no funding (Hermann 2011a;
Hermann 2011b; Nakakura 2012; Norell 1979; Sakai 2005;
Sheppard 2003).
Participants
The 16 studies involved 1565 participants. The studies were rela-
tively small: the median trial size was 74; the largest trial recruited
312 participants (I-SIGHT); and the smallest study recruited 13
participants (Laster 1996).
The average age of participants included in these studies ranged
from 55 to 73 (median value 66 years). The range of ages went
from 18 to 91. In the 15 studies reporting gender, the propor-
tion of women ranged from 1% to 85%, with a median value
of 58%. Eleven studies reported ethnicity: the proportion of the
study population who were white ranged from 9% (I-SIGHT) to
100% (Hermann 2011a; Hermann 2011b), the proportion black
ranged from 0% to 91% (I-SIGHT) and the proportion Asian
ranged from 0% (five studies) to 10% (Ring 2011). Nakakura
2012 and Sakai 2005 were conducted in Japan but ethnic group
was not specifically reported.
Almost all studies included people diagnosed with OAG or OHT
and prescribed ocular hypotensive eye drops. The exception was
the Japanese trial (Sakai 2005) which recruited people diagnosed
with primary angle-closure glaucoma.
Interventions
The interventions varied considerably, although there were a few
common themes as categorised below. For most studies the follow-
up period was categorised as short-term (less than six months).
The exception to this was Muir 2012 which followed up to six
months and Gray 2011 and I-SIGHT followed up to 12 months.
Gray 2011 also collected some follow-up data at 24 months.
Education or education combined with behavioural change
interventions
There were seven studies which had employed some form of edu-
cational programme to improve adherence (Gray 2011; I-SIGHT;
Muir 2012; Norell 1979; Okeke 2009; Ring 2011; Sheppard
2003).
In Gray 2011 patients were allocated to receive either individu-
alised patient care in addition to standard care or standard care
alone. Individualised patient care was provided by a glaucoma
trained nurse and involved an assessment of healthcare needs and
beliefs about illness and medicines (lasting approximately 45 min-
utes), an educational session (of approximately 20 minutes dura-
tion) and an interactive training session, to learn the technique of
instilling eye drops (lasting approximately 10 minutes). Frequency
and purpose of follow-up visits or telephone calls over one year
was agreed with patients. It was expected that the duration of in-
tervention activities would vary according to patient need.
In I-SIGHT the intervention group was given a tailored auto-
mated telephone intervention and tailored printed materials. The
telephone intervention was delivered using interactive voice recog-
nition technology and consisted of individually tailored messages
to encourage adherence. This covered taking medication, keep-
ing appointments, obtaining refills as well as information on glau-
coma. The participant received 12 telephone calls over a nine-
month period. After each telephone call, written materials were
sent to the participants. The control group was given usual care.
In Muir 2012 participants received an educational intervention.
This was a 20-minute individual session with the study co-or-
dinator (who had a background in ophthalmic research but was
not a clinician). The participants watched a video about glau-
coma which explained the structure of the eye and glaucoma and
showed how to instil drops. The language used in the video, and
other printed material, was tailored to the participants’ literacy
which was measured using the Test of Functional Health Literacy
in Adults (Parker 1995). The control group received standard care
as usual from an ophthalmologist.
Norell 1979 implemented a 30-minute education and tailoring
programme using a parallel-group design which took place as part
of the clinic appointment. The intervention group received basic
informationonglaucoma and its treatment supplied by a tape-slide
show and leaflet, then patients’ knowledge and understanding was
checked by an ophthalmic assistant and insufficiently mastered
information was re-emphasised; participants were encouraged to
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ask questions and discuss problems with medication. This was
followed by ’tailoring’ which consisted of a patient interview with
an ophthalmic assistant to ascertain daily routine and to advise on
best times to instil eye drops within the daily routine. Advice was
also given on storage of drops. Finally, times and drop routines
were written for each patient. No description was given regarding
the control group apart from the fact that the participants did not
receive the intervention. The intervention was implemented after
the first 20 days of monitoring. Patients were then followed up
for a further 20 days post intervention to evaluate the difference
between the periods and the groups.
The intervention in Okeke 2009 consisted of a 10-minute educa-
tional video, a structured discussion with the study co-ordinator,
reminder telephone calls and a dosing aid. The educational con-
tent “stressed the importance of regular drop-taking, its rationale and
expected effects, alternatives to eyedrops, and methods to maximize
cooperation, such as linking drops to a daily activity, keeping a drop-
taking calendar diary, and using family members to help in reminding
them”. The discussion with the study co-ordinator aimed “to de-
velop a strategy for improving adherence that included finding the best
time of day to take the medication, distributing a blank calendar di-
ary and going over details of how to keep it, and discussing individual
patient barriers to taking the medication”. The telephone calls were
made once per week for the first follow-up month and then every
other week for the next two months and included a questionnaire
“about drop-taking behavior, difficulty with drops, side effects, and
eliciting questions about therapy” and the dosing aid had audible
and visible alarms. The control group were told it was important
to take drops as prescribed.
In Ring 2011 the intervention group watched a “specifically de-
signed patient education film” and received standard written educa-
tional material. The control group received standard written ed-
ucational material alone. Patients were followed up three months
later to evaluate the difference in outcomes between the two
groups.
Sheppard 2003 evaluated the effectiveness of a glaucoma monitor-
ing nurse-led clinic using a parallel-group design, involving con-
sultations of 15 minutes duration divided into two parts. Part one
consisted of a standard assessment designed tomonitor and record
health details, such as current health status and recent ocular his-
tory and eye examinations including visual acuity, visual field test
and IOP test using Goldmann’s applanation tonometry. Part two
comprised of a semi-structured educational session tailored to in-
dividual patient needs (details not provided). The control group
attended a general ophthalmic clinic involving consultations of 10
minutes duration which included the standard assessment and eye
examinations as above, a fundus examination and the remainder
of time utilised according to each individual clinician (details not
provided). Differences in patient outcomes were followed up at
12 weeks.
Reminder devices
Laster 1996 monitored participants using a medication alarm (the
Prescript TimeCap) reminder device which comprised of a cap
fitted onto a pre-weighed drop bottle. This device comprised of:
• a digital display that showed the time and day of the week
when the container was last opened (the display reminded the
patient when the most recent dose of medication was taken);
• an alarm that beeped when a dose was due and if the beep
was ignored the digital face flashed to provide a visual reminder
that a dose had been missed.
Patients undergoing the control period used a pre-weighed drop
bottle without the TimeCap. As this was a cross-over study each
patient acted as their own control. Patients were monitored for
two periods of 30 days.
Drug comparisons
Drug studies that compared ocular hypotensive therapy met the
inclusion criteria if the dosage frequencies differed and adherence
was compared between the two frequencies
• Hermann 2011a compared brimonidine twice daily with
brimonidine three times daily over four weeks with open and
masked monitoring of adherence.
• Hermann 2011b compared brimonidine twice daily with
brimonidine three times daily over four weeks.
• Laibovitz 1996 compared 2% dorzolamide three times daily
with 2% pilocarpine four times daily using a cross-over design.
Both groups continued to receive 0.5 timolol twice daily.
Patients were monitored for two periods of 14 days.
• Nakakura 2012 compared latanoprost 0.005%/timolol
0.5% plus brinzolamide 1% with dorzolamide 1%/timolol 0.5%
plus latanoprost 0.005%.
• Sakai 2005 compared latanoprost mono-therapy once daily
with multi-therapy of 0.5% timolol twice daily and 1%
dorzolamide three times daily using a parallel-group design.
Participants were monitored for 12 weeks.
• Schenker 1999 compared 0.5% timolol gel once daily with
0.5% timolol solution twice daily using a cross-over design;
patients were monitored for two periods of six weeks.
• Sverrisson 1999 USA and Sverrisson 1999 Europe
compared 2% dorzolamide/0.5% timolol combination therapy
twice daily with 2% pilocarpine four times daily and 0.5%
timolol twice daily using a cross-over design. Participants were
monitored for two periods of 14 days.
Outcomes
Adherence
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All studies measured adherence. There were four main ways of
measuring adherence: by self report, by electronic monitoring,
prescription refills or weighing bottles.
Data on adherence were collected via self report in 10 studies (Gray
2011; I-SIGHT; Laibovitz 1996; Laster 1996; Nakakura 2012;
Sakai 2005; Schenker 1999; Sheppard 2003; Sverrisson 1999
Europe; Sverrisson 1999 USA). Questionnaires were administered
via an interviewer and were delivered at baseline in four studies
(Laibovitz 1996; Sheppard 2003; Sverrisson 1999 USA; Sverrisson
1999 Europe) and on the last day of each cross-over period for the
cross-over studies (Laibovitz 1996; Laster 1996; Schenker 1999;
Sverrisson 1999 USA; Sverrisson 1999 Europe). The remainder
assessed at the end of the study period.
Three studies used the Comparison of Ophthalmic Medica-
tions for Tolerability (COMTol) questionnaire (Laibovitz 1996;
Sverrisson 1999 USA; Sverrisson 1999 Europe) which aims to
measure common side effects of ocular hypertensive therapy and
the extent to which these side effects affect health-related quality
of life, compliance and patient satisfaction (Barber 1997). The
questionnaire includes one adherence question: “How often did
you miss one or more drops?” Patients were asked to mark on a scale
from 0 to 6; 0 = never and 6 = always.
Gray 2011 measured adherence based on the Reported Adherence
to Medication Scale (Horne 1999) using the following questions.
1. “Some people say that it is easy to forget drops. Do you agree or
disagree with the following statement: I sometimes forget to use my
drops”
2. ”How often do you forget drops?”
3. “Some people miss drops out, stop taking them for a while or
adjust the times to suit their needs. Do you agree or disagree with
the following statement: I sometimes miss out drops or alter the times
to suit my own needs”.
4. “How often do you miss/stop using drops or adjust the times to
suit your own needs?”
Patients were then asked to approximate how many drops they
missed per month. Answers were scored using an ordinal scale of
none, 1 to 3, 4 to 6 and 7 ormore. Patients were also askedwhat the
longest period without administering drops was and what caused
them to omit doses. These questions were entered as free text.
I-SIGHT defined non-adherence as self report of missing doses
of any glaucoma medication within one month of the interview.
They also asked about missed doses within seven days and two
weeks.
Laster 1996 asked patients to report the percentage of time (0%
to 100%) they adhered to their eye drop therapy for each of the
two 30-day phases studied.
Nakakura 2012 asked the following question: ”How often do you
forget administration per week?“ (never/within two times per week/
more than three times per week).
Sakai 2005 asked patients how many times they had forgotten to
apply the eye drops, and responses were classified into four groups:
less than once a week, once a week, two or three times a week, and
four or more times a week.
Schenker 1999 measured adherence using the following question:
”During the last two weeks, how often did you miss one or more
doses of test medication“ with the answer classified as never/rarely/
occasionally/frequently/always
Sheppard 2003 conducted structured telephone interviews. Ad-
herence was measured using an 11-point response scale (0 = never
uses drops, 10 = always uses drops) but did not state over what time
period. Participants were also asked if they encountered problems
instilling drops and the reasons for not instilling drops.
Adherence was measured by electronic monitoring in four studies:
• Hermann 2011a and Hermann 2011b used an electronic
monitoring device that was reported to detect eye drop usage
with a sensitivity of 99% and specificity of 98% (confidence
interval not given) (Hermann 2006). In Hermann 2011a
patients were randomised to either a group which were aware or
not aware of adherence monitoring to test whether masking this
information has an effect on adherence whereas in Hermann
2011b no patients were told that their adherence was being
monitored.
• Norell 1979 used a medication monitor. The monitor
consisted of a plastic box with a holder for a 25 ml bottle. The
holder was designed to protect the bottle and to facilitate
replacement of the eye dropper cap. An elastic flap linked to a
micro switch inside the box signalled to the electronic part of the
monitor whether the cap was on or off. A sliding lid in the
bottom of the monitor could be removed to exchange the bottle
and battery but it was sealed when the monitor was given to the
patients. The electronic system recorded information on whether
or not the bottle had been opened during the last hour. When
the monitor was connected to a separate read-out device, this
information, together with the time signal was displayed on an
electrocardiographic recorder. Patients were not told the purpose
of the medication monitor until after data collection was
complete.
• Okeke 2009 used a dosing aid that recorded the time and
date of delivery on an internal, battery-operated chip and had
been previously evaluated to have acceptable accuracy (Friedman
2007). Patients were aware that the devices recorded their drop-
taking.
Gray 2011 measured prescription refill and used this to measure
adherence. It was not stated whether patients were aware of be-
ing monitored for prescription refill adherence. I-SIGHT defined
refill non-adherence as ”failure to refill any glaucoma medication
prescription within a 1-month period after it was prescribed“ as indi-
cated in pharmacy records, or as a physician note on refill non-ad-
herence. No information was provided on whether patients knew
for what reason prescription data was to be collected. Muir 2012
reviewed pharmacy records and determined the ”number of days
without medication“ which was defined as ”the difference between
the number of days that medication was available to the subject ac-
cording to the pharmacy records and the prescribed dosing and the
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number of days that medication was required over the study period“.
Again, no information is provided on whether patients knew for
what reason prescription data were to be collected.
Two studies weighed the eye drop bottle to measure adherence.
Ring 2011 measured adherence by weighing bottles. The weight
of eye drop bottle was taken before and after the study period and
the target weight as per prescriptionwas compared to actual weight
afterwards. Laster 1996 weighed each bottle before the interven-
tion and weighed it again on return so the amount of medication
could be calculated. It is unclear in either study whether patients
were told that bottles would be weighed to calculate adherence to
eye drop therapy.
Persistence
In Gray 2011 patients who discontinued therapy and did not
restart during the study periodwere defined as not being persistent.
Laibovitz 1996; Sverrisson 1999 Europe and Sverrisson 1999 USA
reported the numbers of patients who continued or completed
treatment.
Intraocular pressure
Only a few studies declared how they measured IOP. Those that
did reported they used Goldman’s Applanation Tonometer. For
Gray 2011 measurements were taken from the medical records
of patients at 12 months immediately after the follow-up period
and then at 24 months. In Nakakura 2012 an experienced oph-
thalmologist measured IOP at baseline, four weeks and 12 weeks.
Okeke 2009 provided little information other than reporting that
intraocular pressure was measured before and after the interven-
tion. Measurements were taken at each visit between 10am and
noon prior to washout, at baseline and at four-week intervals for
Sakai 2005. For Schenker 1999 they were taken immediately be-
fore instillation (trough/0 hour), and two hours after instillation
(peak) of morning medication at three-week intervals. Measure-
ments were taken at trough and peak at baseline and the beginning
and end of each cross-over period for Laibovitz 1996, Sverrisson
1999 USA and Sverrisson 1999 Europe.
Visual field defects
Four studies assessed for visual field defects (Laibovitz 1996; Sakai
2005; Sverrisson 1999 USA; Sverrisson 1999 Europe) using the
Humphrey FieldAnalyser, except in Sverrisson 1999 Europewhere
some sites used an Octopus perimeter. All tested at baseline and
at the end of the treatment period.
Quality of life measures
Three studies (Laibovitz 1996; Sverrisson 1999 USA; Sverrisson
1999 Europe) measured the effect of eye drops on quality of life as
part of the COMTol questionnaire (Barber 1997). Patients were
askedwhether their quality of life was interferedwith by side effects
and activity limitations. Responses were marked on a scale of 0 to
5; 0 = not at all, 5 = extremely. This was measured at baseline and
after each treatment period.
Adverse events
Only the drug comparison studies reported adverse events. In the
three studies using the ComTol questionnaire (Laibovitz 1996;
Sverrisson 1999 USA; Sverrisson 1999 Europe) participants were
asked about ocular symptoms (burning/stinging; red, itchy, dry
eyes; discharge; swelling; tearing), taste (bitter/unusual), vision
(blurred vision, dimming of vision, trouble seeing at night), ac-
commodation (trouble reading, trouble focusing near-to-far) and
brow ache. Participants were asked how frequently any of the
above symptoms occurred on a scale of 0 to 6 (0 = never, 6 =
always) and how bothersome the symptoms were also on a scale
of 0 to 6 (0 = not bothered, 6 = extremely bothered). In addition,
headache was reported by participants in both studies. Sakai 2005
did not specify the questions asked to determine adverse events,
yet reported that the following ocular adverse effects were ob-
served: mild irritation, conjunctival hyperaemia, superficial punc-
tate keratitis and eye lid pigmentation. The authors also reported
the systemic adverse events of bradycardia and orthostatic hyper-
tension. Schenker 1999 also did not specify the questions asked,
yet reported the following symptoms: upper respiratory infection,
blurred vision, eye burning/stinging, headache, conjunctival injec-
tion and eye itching. Nakakura 2012 asked about stinging/burn-
ing, foreign body administration, blurred vision, conjunctival hy-
peraemia and ”comfortableness“. Conjunctival hyperaemia and
superficial punctate keratopathy were also assessed clinically.
Patients’ knowledge of glaucoma
Four studies measured patients’ knowledge or understanding of
glaucoma (Gray 2011; Okeke 2009; Ring 2011; Sheppard 2003).
Three of the studies used different measures. Gray 2011 com-
pared patients’ knowledge of glaucoma between the intervention
group and control group administering a questionnaire (the Re-
vised Glaucoma Adherence Questionnaire, GAQ-R, Gray 2010)
by interview at the end of the 12-month follow-up period. Ring
2011 asked 10 questions on patients’ knowledge of glaucoma
(Appendix 12) at baseline and threemonths after the intervention.
Sheppard 2003 assessed patients’ understanding of glaucoma by
two questions: ”What is glaucoma?“ and ”How does glaucoma af-
fect the eye?“ using a multiple choice format before and after the
intervention. No information was provided in Okeke 2009 about
how knowledge of glaucoma was measured. Muir 2012 stated that
they collected data on ”self-reported disease knowledge“ but did not
report this outcome.
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Costs
None of the studies reported the costs of the interventions.
Other outcomes
Gray 2011 measured other outcomes including patients’ percep-
tion of glaucoma as an illness, the Revised Illness PerceptionQues-
tionnaire, their beliefs about glaucoma (Moss-Morris 2002), Be-
liefs about Medicines Questionnaire (Horne 1999) and patients’
satisfaction with quality of care, the Patient Enablement Instru-
ment (Howie 1998). I-SIGHT assessed patients as non-adherent
to appointments if physicians hadmade a record as such in notes or
if there were no rescheduling of appointmentwithin threemonths.
Excluded studies
Reasons for excluding studies are presented in the ’Characteristics
of excluded studies’ table. The majority of studies were not ran-
domised trials and those that were did not measure adherence.
These were mainly drug trials. One drug trial (Shibuya 2003) did
measure adherence, however, the two ocular hypotensive thera-
pies being compared were instilled via the same frequency (’once a
day’) and, therefore, we could not include this study. The authors
of this study did not find a significant difference in adherence be-
tween the two ophthalmic solutions. We contacted authors of five
studies for more information before a decision regarding eligibility
could be made. A French study (Bron 2004) did question patients
about their adherence level but did not publish the results. When
asked for the results the authors stated that, ”such an evaluation is
unreliable“. Very little information was available regarding a study
by Hunter 1999, found via the UK National Research Register.
As there was no published paper and we were unsuccessful in con-
tacting the author, we could not proceed further with this study.
Risk of bias in included studies
Details of ’Risk of bias’ assessments for individual trials are pre-
sented in the ’Risk of bias’ tables and figures (Figure 1; Figure 2).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Within the published papers, information was sparse concern-
ing sequence and allocation concealment. Only a minority of
studies reported adequate methods of sequence generation (Gray
2011;Hermann 2011a;Hermann 2011b; I-SIGHT;Okeke2009;
Sheppard 2003) and only Gray 2011,Hermann 2011b andOkeke
2009 reported adequate methods to conceal allocation prior to
assignment. Following contact with authors, we were able to
judge more accurately for some studies. A further five studies
(Laibovitz 1996; Laster 1996; Schenker 1999; Sverrisson 1999
USA; Sverrisson 1999 Europe) described adequate sequence gen-
eration, either by using a computer-generated system or by draw-
ing lots. We judged one quasi-randomised study (Sakai 2005) as
high risk for using a rotation method, one trial (Norell 1979) as
unclear, for not providing adequate information, and Ring 2011
ran the educational film on random days, rather than randomly
allocating participants.
Six studies concealed allocations adequately until assignment
using sealed opaque envelopes (Gray 2011; Hermann 2011b,
Laibovitz 1996;Okeke 2009; Schenker 1999; Sverrisson 1999
USA; Sverrisson 1999 Europe). We graded three studies as high
risk (Laster 1996; Ring 2011; Sakai 2005) for not concealing allo-
cations and the rest were unclear (Hermann 2011a; Norell 1979;
Sheppard 2003), as we could not obtain adequate information.
Blinding
We assessed masking according to those involved, e.g. the par-
ticipants, study personnel involved in data collection such as in-
terviewers and outcome assessors involved in data analysis. Much
of the information regarding masking was obtained through con-
tacting authors rather than the published evidence. Due to the
nature of the included studies it was particularly difficult to mask
participants. It could be argued that for drug trials, placebo drops
could be used so that the frequency of instillation was the same
for both groups, but since the hypothesis is that adherence may be
related to the frequency of drop instillation this would be coun-
terproductive.
For the studies involving interventions such as education, indi-
vidualised care planning and reminder devices, ’performance bias’
is an integral part of the intervention so we did not grade these
studies for this parameter.
With respect to detection bias, Gray 2011, Hermann 2011a,
Hermann 2011b, Laibovitz 1996, Norell 1979, Okeke 2009,
Schenker 1999, Sverrisson 1999 USA and Sverrisson 1999 Europe
reported that their studies were observer-masked or used tech-
niques such as electronic monitoring where masking was not rel-
evant. The remaining studies did not state any masking details
which made judgements difficult. We judged four studies as high
risk for detection bias; three (Laster 1996; Nakakura 2012; Ring
2011) had no masking procedures in place and the other (Sakai
2005) masked the interviewer but not the outcome assessor. We
classified Sheppard 2003 as unclear.
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Incomplete outcome data
We judged five studies as low risk for incomplete outcome data;
for either having no missing data or adequately addressing miss-
ing outcome data, with attrition rates of less than 20% (Gray
2011; Hermann 2011a; I-SIGHT; Nakakura 2012; Norell 1979).
We judged two studies as high risk (Sverrisson 1999 Europe;
Sverrisson 1999 USA). For Sverrisson 1999 USA and Sverrisson
1999 Europe, the attrition rates were unclear from the paper and
no further clarification was provided by study authors. The num-
ber of participants excluded from analyses varied across outcomes.
The European study (Sverrisson 1999 Europe) suffered the great-
est number of exclusions (22/93 (24%)) for the quality of life data.
The numbers of participants involved in intraocular pressure and
visual field analyses were unavailable for this study and, therefore,
may also have exceeded 20%. In the remaining studies it was dif-
ficult to judge the impact of missing data and we graded these as
unclear.
Selective reporting
As we did not have access to study protocols we could not judge
studies as low or high risk of bias for this aspect. We marked
all studies as unclear for selective reporting due to insufficient
evidence, with the exception of Gray 2011 where it was clear from
the report that all outcomes were reported.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings: education and individualised care planning; Summary
of findings 2 Summary of findings: drug regimen
We did not perform a meta-analysis because there was clinical het-
erogeneity with respect to the interventions, and methodological
heterogeneity with respect to the measurement of outcomes.
Adherence
Patient education or patient education combined with other
behavioural change interventions
Table 2 summarises the effect of patient education or patient edu-
cation combined with other behavioural change interventions on
adherence to ocular hypotensive therapy.
Gray 2011, Norell 1979 and Okeke 2009 reported that adher-
ence changed significantly with education and other behavioural
change interventions. In Gray 2011 the proportion of people who
were classified as adherent during the one-year follow-up was 70%
in the intervention group compared to 43% in the control group.
In Norell 1979 13% of the time patients exceeded eight-hour dose
intervals in the intervention group compared to 24% in the con-
trol group during a 20-day period. In Okeke 2009 there was a
higher adherence rate in the intervention group over three months
(0.73) compared to the control group (0.51). All these differences
were clinically and statistically significant.
I-SIGHT,Muir 2012, Ring 2011 and Sheppard 2003 did not find
any statistical differences between the intervention and control. In
I-SIGHT 30% of the intervention group and 27% of the control
group did not report missing drops in the last month. In Muir
2012 the intervention group had, on average, 63 days without
medication compared to 65 in the control group over six months.
In Ring 2011 adherence as defined in the study (eye drop bottles
within 10% of target weight) was similar between intervention
and control groups. In Sheppard 2003 it was difficult to judge as
no data were presented to support the statement that there were
no differences between intervention and control groups.
Reminder devices
Laster 1996 was a cross-over study that reported data without
providing information on the cross-over periods. Out of 13 par-
ticipants, five people reported being adherent (100% compliance
over 30 days) when using the TimeCap reminder device, one par-
ticipant reported being adherent when not using the TimeCap
device and seven were not adherent irrespective of whether using
the device or not. It is difficult to interpret these data without
knowing more information as to the time periods when the data
were collected. Laster 1996 also reported that people using the
TimeCap instilled approximately 3 grams more (mean difference
(MD) 2.87, 95% confidence interval (CI) 1.70 to 4.03, P < 0.001)
of eye drops over a 30-day period than those without.
Comparison of different drug regimens
Table 3 summarises the effect of drug regimen on adherence. The
’simpler’ dosing regimen is classified as the intervention in this
table. The specific dosing regimens are summarised in Table 1.
Two studies measured adherence using an electronic monitoring
device (Hermann 2011a; Hermann 2011b) and the other six stud-
ies measured adherence using self report.
The table shows that in all eight studies the simpler dosing regimen
was associated with greater adherence, although these differences
were not always statistically significant, There were some uncer-
tainties as to the analysis of the cross-over studies because in all
cases they reported data for both periods combined. In addition,
in most studies there were also differences in the type of drug used
which may mean that drawing conclusions as to the association
between adherence and simpler drug regimens may be too sim-
plistic.
Monitoring
Hermann 2011a compared open and masked monitoring and
measured adherence using an electronicmonitor. They found little
effect of type ofmonitoring on adherence (see table 3 of trial report
on page e303). The adherence rate in people taking brimonidine
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twice daily was 69.5% (standard deviation (SD) 17%) in people
who were informed that they were being monitored compared to
77.1% (SD 6.0%) in people who did not know that they were
being monitored. In people taking brimonidine three times daily
the open monitoring group had an adherence rate of 65.3% (SD
14%) compared to people in the masked monitoring group who
had an adherence rate of 62.4% (SD 9.1%).
Persistence
There were fewer data reported on persistence.
Patient education or patient education combined with other
behavioural change interventions
In Gray 2011 persistence was defined when patients who discon-
tinued therapy did not restart during the study period. Overall
there were 17/127 patients who did not persist. In the interven-
tion group 59/64 persisted compared to 51/63 in the standard
care group (risk ratio 1.14, 95% CI 0.99 to 1.31).
Comparison of different drug regimens
In Laibovitz 1996 72/75 (96.0%) patients continuedwith the sim-
pler regimen (dorzolamide three times daily) and 51/74 (68.9%)
continued with the more complicated regimen (pilocarpine four
times daily). However, these data represent the two periods of this
cross-over study combined - in fact 75 patients in total were re-
cruited into the study but no information on persistence in the
different time periods was reported.
Sverrisson 1999 Europe did not find much difference between
two groups; 87/92 (94.6) completed treatment with the simpler
regimen (combination treatment with dorzolamide/timolol) com-
pared to 84/91 (92.3%) who completed treatment with the more
complex regimen. Again the cross-over design has been ignored in
this analysis. In the US study (Sverrisson 1999 USA) the results
were different: 90/93 (96.8%) completed treatment with the sim-
pler combination regimen compared to 60/95 (63.2%) with the
more complex regimen.
Intraocular pressure
Intraocular pressure was found to be significantly reduced in only
one of the four studies that measured this outcome (Sakai 2005).
They found amean difference of -2.30 (95%CI -3.85 to -0.75, P =
0.004). This difference is likely to be independent of the adherence
results as there was no difference in adherence between the two
groups as reported above. There was no difference in intraocular
pressure for three studies. Laibovitz 1996 measured at peak at the
end of each study period (MD 0.10, 95% CI -0.43 to 0.63, P
= 0.71) and Schenker 1999 also measured at peak at the end of
each study period (MD -0.10, 95% CI -0.79 to 0.59, P = 0.78).
Although both studies measured intraocular pressure at several
intervals, we have reported the peak measurement as this result
was presented by both studies. We could not analyse intraocular
pressure for the remaining two studies (Sverrisson 1999 USA;
Sverrisson 1999 Europe), as the number of participants involved
was not stated in the paper and the authors could not provide these
data when contacted. According to the published results, however,
a significant difference was not found between treatment groups
in both studies.
Of the new studies included in the current update, Hermann
2011a reported baseline intraocular pressure only and Gray 2011
foundnodifference in intraocular pressure between the twogroups
at 12months and 24months, but there was some suggestion of de-
creased ”fluctuation“ in the intervention group at over 24 months
(Table 4). Okeke 2009 found no difference between the interven-
tion groups with respect to intraocular pressure but did not report
the actual data. They also did not find any association between ad-
herence rate and intraocular pressure. Nakakura 2012 found very
similar intraocular pressure in both groups (14.1 mmHg (SD 2.7)
versus 14.2 mmHg (SD 2.7).
Visual field defects
We could only analyse the results of one study (Sakai 2005) for
visual field defects, and we did not find a significant difference
between the two groups (MD 0.90, 95% CI -3.85 to 2.05, P
= 0.55). We could not analyse the results for Laibovitz 1996 as
paired data were not presented and for Sverrisson 1999 USA and
Sverrisson 1999 Europe due to missing data (as above, we could
not obtain data for the number of participants involved in visual
field testing). The study authors for all three studies did not find a
significant difference for emerging or worsening of defects. None
of the new studies included in this 2012 update (Gray 2011;
Hermann 2011a; Okeke 2009; Ring 2011) reported visual field
defects.
Quality of life
Quality of life was analysed in three studies via the self report
COMTol tool (Barber 1997). Side effects for patients prescribed
pilocarpine drops alone or pilocarpine plus timolol drops inter-
fered with quality of life; both of these regimes required drops to
be instilled four times a day (Laibovitz 1996: MD -1.60, 95% CI
-2.04 to -1.16, P < 0.001; Sverrisson 1999 USA and Sverrisson
1999 Europe: MD 1.10, 95% CI -1.35 to -0.85, P < 0.001, I2
= 60%). There were also more reported activity limitations when
the frequency of drop instillation increased (Laibovitz 1996: MD
-1.60, 95% CI -2.04 to -1.16, P < 0.001; Sverrisson 1999 USA
and Sverrisson 1999 Europe: MD -0.72, 95% CI -0.97 to -0.47,
P < 0.001, I2 = 92%). Patients instilling drops less frequently, dor-
zolamide three times a day (Laibovitz 1996) or dorzolamide/tim-
olol combination drops (Sverrisson 1999 USA; Sverrisson 1999
Europe) twice a day, reported significantly less interference to their
quality of life by side effects or activity limitations.
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Patient knowledge
Gray 2011 found that patients who received education combined
with an individualised package had better knowledge of glaucoma
and its treatment compared to those who received standard care.
The median knowledge score (Gray 2010) was 14 (range 2 to 18)
for the intervention group and 6 (range 0 to 17) for the control
group (Mann-Whitney P < 0.001).
Data on patient knowledge were provided by Ring 2011. For two
out of the 10 questions, the control group showed greater improve-
ment in knowledge over the three-month period (i.e. answered
questions correctly). However, for most questions the differences
between intervention and control groups three months after the
intervention were not statistically significant.
Okeke 2009 and Sheppard 2003 reported no differences between
intervention and control groups with respect to patient knowl-
edge, but Okeke 2009 did not report the actual data. Muir 2012
collected but did not report data on patient knowledge.
Costs
No data were reported on the cost of the interventions.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Simplified drug regimen for improving adherence to ocular hypotensive therapy
Patient or population: people with glaucoma or ocular hypertension
Settings: outpatients
Intervention: simplified drug regimen
Comparison: standard care
Outcomes No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Adherence 650
(8)
⊕©©©
very low1
All studies reported a better ad-
herence rate in the group with the
simpler drug regimen; in 3 stud-
ies this differencewas statistically
significant. Different measures of
adherence meant it was difficult
to estimate overall treatment ef-
fect
Persistence 265
(3)
⊕©©©
very low1
2 out of 3 studies found that the
people using the simpler drug reg-
imen had a higher persistence,
however all 3 studies were short-
term cross-over studies and time
periods were not reported
Intraocular pressure 503
(5)
⊕©©©
very low1
Overall there was little evidence of
any effect on IOP
Visual field defects 301
(4)
⊕©©©
very low1
None of the studies found signif-
icant effects on visual fields but
were of short duration
Quality of life 265
(3)
⊕©©©
very low1
In all 3 studies quality of life
was assessed using the COMTol
questionnaire. There were more
reported activity limitations when
the frequency of drop instillation
increased
Adverse effects 650
(8)
⊕©©©
very low1
Interventions too different to come
to a consensus as to adverse
effects
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
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change the estimate.
Very low quality: We are very uncertain about the estimate.
1We downgraded to very low because (i) trials were at risk of performance and other biases, (ii) data from cross-over trials had not been
analysed appropriately, and (iii) there was inconsistency in trial results.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
D I S C U S S I O N
Summary of main results
There was some evidence that patient education combined with
other more complex behavioural change interventions improved
adherence to ocular hypotensive therapy (Summary of findings
for the main comparison), however overall the findings were not
conclusive. The studies were variable quality; some studies were
at considerable risk of bias, and in general the length of follow-up
was short, i.e. less than six months. Only three studies followed
up for six months or more.
It was not possible to combine the results of different studies due
to differences in reporting outcomes. In three studies, people who
received patient education combinedwith othermore complex be-
havioural change interventions to improve adherence to eye drops
were more likely to take their medication as prescribed. However,
in four studies no effect was observed. The intervention was more
complex and individually tailored in the studies that showed an
effect. There was less information on other outcomes such as per-
sistence and intraocular pressure, and no information on visual
field defects and quality of life.
There was weak evidence as to whether people on simpler drug
regimens were more likely to adhere and persist with their ocular
hypotensive therapy (Summary of findings 2). Again studies were
of variable quality and short-term. A particular problem was the
interpretation of cross-over studies which in general were not re-
ported correctly.
One study investigated a reminder device and monitoring. How-
ever, this study was small and inconclusive.
Overall completeness and applicability of
evidence
Follow-up and duration of intervention
Follow-up of patient outcome in the studies which incorporated
an educational intervention ranged from 20 days to one year (24
months for a few outcomes) with the most being around three
months. Reardon 2011 found that persistence significantly dimin-
ishes at the end of the first year for patients newly prescribed ocular
hypotensive therapy. Arguably, a longer follow-up period would
be most efficacious in understanding the long-term effects of these
types of interventions. Similarly, the reminder device (Laster 1996)
was tested for only two periods of 30 days. Monitoring for a longer
period of time may have given a more accurate picture of the de-
vice’s true effect and may have produced a different result.
Some of the interventions focusing on education were of extremely
short duration.One (Norell 1979) lasted 30minutes and the other
(Sheppard 2003) 15 minutes. In Ring 2011 intervention lasted
for as long as the video (not specified). More recent studies have
designed interventions which have lasted for longer periods, in-
corporating long-term support: Okeke 2009 provided reminders
for up to three months, Gray 2011 provided nursing support for
up to one year and I-SIGHT provided advice and reminders via
an automated tailored health communication over nine months.
More and better designed studies are required in order to under-
stand the effectiveness of short versus long-term interventions.
’Hawthorne effect’
For Sheppard 2003, a significant difference was not found be-
tween the groups. When scores were compared to baseline re-
sults, however, both groups were found to have significant im-
provement in adherence levels. This result potentially masks the
true effect of the intervention and may reflect the ’study effect’
often termed the ’Hawthorne effect’ (Leonard 2006; Leonard
2008; Mangione-Smith 2002). Both groups may have changed
behaviour as a result of being involved in a research study due to
the additional attention received. Specific details for care received
by the control group were limited for this study; the authors stated
that, ”time was utilised according to each individual clinician“. A
number of factors may be involved; control group patients may
have becomemore interested in their disease and askedmore ques-
tions than theywould have done normally. Adherence was assessed
at baseline and at completion and, therefore, patients may have
changed their behaviour by adhering to their drop regime, know-
ing that they would be questioned about their adherence level
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again at the end of the study as they had been at the beginning.
Doctors may have spent more time than usual discussing eye drop
therapy and adherence issues with control group patients know-
ing that they were also being observed. If the study had been of
longer duration, for example, with a one-year follow-up period,
the ’Hawthorne effect’ may have subsided over time. Whilst the
Hawthorne effectmay be particularly pertinent to Sheppard 2003,
it may also have been a factor in the outcomes of the other studies.
This is with regard to what researchers tell participants about the
study, especially concerning what and how the outcomes are to be
measured. In the case of this review, it is unclear in many of the
studies whether patients knew in advance how adherence was to
be measured objectively if they knew at all. Usually, good ethical
practice demands transparency with patients but this may have
the potential to cause reactivity bias. As reported in this review,
Hermann 2011a found that there was no significant difference in
adherence between those patients masked and unmasked to ad-
herence monitoring. Although more research is needed to further
our understanding of this issue.
Measures of adherence
Ten studies measured adherence via self report.This is said to be
unreliable as patients tend to over-estimate their adherence level,
as Rotchford 1998 found when self report results were compared
with prescription refill rates. The subjective measure of self report,
however, is the most utilised method for assessing adherence in
glaucoma as in other long-term conditions (Chang 1991; Nelson
2006; Senior 2004; Ulrik 2006). Three of the studies (Laibovitz
1996; Sverrisson 1999 USA; Sverrisson 1999 Europe) in our re-
view used the previously validated COMTol tool (Barber 1997).
Gray 2011 and Schenker 1999 validated the reliability of the ques-
tionnaire used during their studies and the remainder did not dis-
cuss validation of the tool used. All were numerical scales which
allowed patients to mark along the scale where they thought their
answer should be, without judgemental or leading questions. Nu-
merical and Likert scales are frequently used (Ross 2004; Treharne
2004) and have been validated (DiMatteo 1993; Horne 1999;
Moss-Morris 2002; Wetzels 2006) for adherence studies involving
patients with long-term conditions. They can provide a construc-
tive measure, yet one must bear in mind that positive findings
are likely to over-estimate the true effect. Sakai 2005 appeared to
have the least robust tool which asked patients whether they for-
got drops on a narrow scale, ranging from less than once a week
to four or more times a week. The categories used may have led
patients to answer ’less than once a week’. This study compared
the least frequent dosage (once a day) with a rather complicated
regime of one drop three times a day and another drop twice a
day and found no difference between the groups. It may well have
been the assessment tool that produced such positive results for
both groups rather than the interventions being compared.
Measures of persistence
Prescription refill rates and dispensing counts are objective meth-
ods for assessing patients’ continuity of therapy and have been used
successfully in ophthalmology (Reardon 2004; Reardon 2011;
Rotchford 1998). While these methods accurately measure persis-
tence, they do pose some problems; an accurate measurement of
prescribed drops can usually be obtained via the patient’s doctor
- obtaining dispensing information is sometimes more difficult if
patients use several pharmacies. Also, patients may obtain repeat
prescriptions for a number of medications and, therefore, receive
their eye drops as part of their regularly repeated supply. This does
not necessarily mean that the drops will be used as prescribed or
used at all. Combining both adherence and persistence measures
may help to combat the latter issue.
Monitoring device
The monitoring devices used by Norell 1979 and Okeke 2009
could be viewed as the most reliable tools. It is particularly un-
fortunate that we could not assess the risk of bias effectively for
Norell 1979 in order to provide a more comprehensive assessment
of methodological quality. A monitoring and reminder device has
been developed (Boden 2006; Flowers 2006). This is a container
that houses a drop bottle and records the handle on the device
being depressed to indicate drop instillation. There is also a visual
and auditory function to act as a reminder for patients to instil
drops. This appears to be an updated version of the device used in
the Laster 1996 study and, therefore, has similar issues regarding
monitoring and for patients wishing to travel. The device has been
designed for use with travoprost drops only, however the software
for this device has been withdrawn from the UK and is no longer
available.
Another device (Hermann 2006) fitted with a microprocessor is
designed to attach to a normal size bottle to record tilting and
squeezing of the bottle. The advantages this has over the previ-
ous designs are that it is smaller; the microprocessor has increased
data safety, data can be downloaded onto a personal computer and
patients can carry the device around easily. The device is hidden
under a drop bottle creating a normal bottle appearance, thereby
increasing the likelihood of patients being unaware of monitoring.
This device does appear to be promising, but until more accurate,
cost-effective monitoring devices like this are available, methods
of self report and prescription refill used independently, or in com-
bination, will continue to be the standard assessment tools for
measuring drop usage.
Another device available is theMedicationEventsMonitoring Sys-
tem (MEMS, http://www.aardexgroup.com), a white plastic con-
tainer with a screw top in which the eye drop bottle is stored until
needed for drop instillation, that is, it is a bottle in a bottle and
therefore it is easy to tip out the drop bottle when there is a need
to instil eye drops. An electronic record is made every time the top
is unscrewed. The battery is reported to last for 36 months. There
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are various sizes of the MEMS so it is quite probable it will store
all types of glaucoma eye drop bottles. The MEMS has been used
successfully to measure adherence to glaucoma treatment (Sleath
2012). The device is relatively cheap to purchase and it is easy to
train patients in its use. The drawbacks of the MEMS include, on
the one hand, that it may act as a reminder to patients and on the
other that it could be a barrier to taking medicines as prescribed.
This is because it requires an additional action (unscrewing the
bottle) which could be sufficient to put off some people. Also,
there is no way of knowing whether the patient actually instils the
eye drops once unscrewed and, vice versa, patients could leave off
the screw top but still be putting in eye drops. To date no RCT
has reported using the MEMS to measure adherence to ocular
hypotensive medication, however its potential is worthy of explo-
ration in future studies.
Co-morbidity
We stated in the protocol that we would include studies that
reported involuntary non-adherence, e.g. due to co-morbidity.
Three studies (Gray 2011; Okeke 2009; Sheppard 2003) reported
that they asked participants what problems they had instilling
drops.
Clinical outcomes
Most of the studies measuring education or reminder interven-
tions did not assess clinical outcomes. As these studies were short-
term it is unlikely that changes in clinical outcomes such as in-
traocular pressure, visual field defects or optic nerve head changes
would have been significantly different between groups. A study
(Sakai 2005) that did assess clinical outcomes found evidence that
one drug was more efficacious in terms of reducing intraocular
pressure. This study, however, did not find a significant difference
between the groups regarding adherence to therapy and, there-
fore, as previously discussed the difference in pressures was likely
to be unrelated to the adherence level and more related to the
drug, whilst the adherence results may be due to the measuring
tool used. The remaining four studies (Laibovitz 1996; Schenker
1999; Sverrisson 1999 Europe; Sverrisson 1999 USA) found no
evidence that patients’ intraocular pressures were significantly re-
duced in the groups with better reported adherence levels. Gray
2011 report no difference in intraocular pressure between the in-
tervention and control group but did find a statistical difference in
intraocular pressure fluctuations at 24 months in that it was lower
in the intervention group.
Sakai 2005 had sufficiently robust data with which to identify that
there were no differences in visual field defects between the two
groups. As mentioned above, the data from the remaining three
studies could not be analysed (Laibovitz 1996, Sverrisson 1999
Europe; Sverrisson 1999 USA). Only one study (Okeke 2009)
measured the optic disc but the categories were not exclusive.
Quality of the evidence
The overall quality of the evidence for the different outcomes is
summarised for the main comparisons in Summary of findings for
the main comparison and Summary of findings 2.
In general we graded the evidence as ’low’ or ’very low’ (Gordon
2008). This is because we considered the included trials to be at
risk of bias in one or more parameters, there was inconsistency in
the findings between trials, and in some cases sufficiently sparse
data such that the findings were imprecise. This means that future
research is likely to have an important impact on the estimates of
effect and in some cases we are very uncertain about the estimates
of effect.
Potential biases in the review process
It is possible that unfavourable findings did not reach publication.
A failure to publish unfavourable results leads to an accumulation
of literature favouring benefits. Bias distorts systematic reviews and
meta-analyses and encourages the use of questionable treatments (
Dwan 2008). This is less of an issue for our review sincewe have not
found sufficient evidence yet tomake definitive recommendations.
For completeness, we invite readers to send us any published or
unpublished studies that meet our inclusion criteria, that we may
have missed.
Publication bias may be less of a problem in the future with the
use of trial registries. For this update we searched the clinical trial
registries and have a total of 16 unpublished and ongoing studies
that will be included in future updates of this review.
Agreements and disagreements with other
studies or reviews
A systematic review by Olthoff 2005 found the quality of exper-
imental studies to be poor, as did the first version of our review
(Gray 2009). However since then the quality of some studies ap-
pears to have improved, albeit no definitive trial has yet been pub-
lished. Five intervention studies were included; three of these were
RCTs (Gray 2011; Norell 1979; Ring 2011) and, therefore, are
included in our review. Norell 1979 was the only one to be judged
as good quality by Olthoff 2005 who also found the education
and tailoring intervention to be the most convincing. Unfortu-
nately, Norell was the only author amongst our included studies
that we could not contact for more information regarding missing
methodology information and, therefore, we could not judge the
study as good quality.
A recent update of a Cochrane review (Haynes 2008) found that
interventions for chronic health conditions were mostly complex
and not very effective; even the most effective did not lead to large
improvements in adherence and clinical outcomes. Haynes 2008
also found a plethora of interventions which could not be com-
bined into a meta-analysis. As for our review, most of the studies
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suffered from low power due to small sample size. Haynes 2008
recommended that high priority should be given to fundamental
and applied research, concerning innovations to assist patients in
following prescriptions for long-term medical disorders.
We found only limited evidence to support the effectiveness of
simplifying medication regimes, in contrast to van Dulmen 2007
who found that simplification of the medication regimen led to
better adherence following a review of 36 systematic adherence
reviews in specialities other than ophthalmology. The difference
may be accounted for by the larger number of studies and result-
ing higher number of patients involved, or that the method of
administration may have had an effect (oral versus eye drop).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although the findings of this review suggest that patient educa-
tion combined with more complex behavioural change interven-
tions may improve adherence to ocular hypotensive therapy, there
is insufficient evidence to advocate any particular intervention at
present. Educating patients about their condition, teaching them
how to instil eye drops, providing reminders and working individ-
ually with patients to help them manage their eye drop routines
are all aspects of care which have provided positive findings for
improving adherence levels. In addition to the above, simplifying
drop regimes may also be beneficial, but until there are more con-
vincing results, we are unable to make more substantial clinical
recommendations. However, in the absence of robust estimates
of effectiveness, and in particular any evidence of effect on pro-
gression of the disease, it is not possible to address the issue as
to whether investment in improving adherence is warranted, al-
though in theory it would seem to be a sensible strategy.
Implications for research
This review identified three problems with the published literature
on this topic:
1. Generally, published studies are too short, although more
recent studies have had longer follow-up of outcomes: they do
not provide useful information on whether interventions to
improve and maintain adherence to therapy are effective over the
long term. Glaucoma and ocular hypertension are chronic
conditions: adherence to therapy needs to be maintained over
the long term. We suggest that patients should be followed up
for at least one year.
2. Standardised outcomes are needed: this review has been
limited by the fact that a wide range of outcomes were reported.
This has meant that it was not possible to pool data between
studies and produce reliable estimates of treatment effect. Ideally
a core outcome set should be developed that would include the
views of people who take these medications on a regular basis.
3. Better reporting of studies is needed: we encountered
difficulties with the reporting and interpretation of the cross-over
studies in particular. We recommend that authors follow standard
reporting guidelines, for example, CONSORT guidance has
been produced to assist in the writing of RCTs (Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gray 2011
Methods Randomised, single-centre, observer masked, parallel-group study
Duration: 24 months
Participants Country: UK
Setting: hospital outpatient clinic
Target number of participants: 127
Gender: 64 men, 63 women
Age range: 30 to 91, mean age 66 years
Ethnicity: 114 (90%) white, 8 (6%) black, 5 (4%) other
Inclusion criteria: patients newly prescribed ocular hypotensive eye dropswith a diagnosis
of OAG, normal tension glaucoma, pseudo-exfoliation glaucoma, pigment dispersion
glaucoma or OHT
Exclusion criteria: patients unable to give informed consent or patients already prescribed
a complicated drop regime for another eye condition
Interventions Intervention group: individualised programme of care carried out by an ophthalmic-
trained nurse based on an assessment that takes into account factors such as othermedical
conditions, additional medications, independence with daily living activities, potential
problems managing an eye drop regime and beliefs about medications. Patients also
continue to receive the information, advice and training they would normally be given
within the outpatients department
Control group: usual care; patients receive the information, advice and training they
would normally be given within the outpatients department
Follow-up: 1 year
Outcomes Persistence of therapy measured by counting prescription and dispensing data
Adherence to therapy assessed through self report via interviewer-administered question-
naire
Beliefs about illness and medicines assessed through self report via previously validated,
interviewer-administered questionnaires
Patient enablement assessed through self report via previously validated, interviewer-
administered questionnaires
Intraocular pressure
Notes Funding sources: part-funded by Pfizer
http://www.controlled-trials.com/ISRCTN13706134
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation was
conducted by a statistician with no involve-
ment in data collection. Patients were allo-
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Gray 2011 (Continued)
cated to receive either individualised patient
care in addition to standard care or stan-
dard care alone. Stratified random sampling
ensured equal proportions of patients within
each arm from specialist glaucoma and gen-
eral ophthalmic clinics, to reduce the risk of
confounding factors from potential clinical
management inequalities” Page 257
Allocation concealment (selection bias) Low risk “Allocations were concealed in opaque sealed
envelopes by personnel with no involvement
in the study. Envelopes were then passed onto
a study coordinator with minimal involve-
ment in the study. The study coordinator was
responsible for opening envelopes as patients
were recruited and contacting the interven-
tion nurse to inform her as new patients were
randomised to the intervention-arm.” Page
257
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The researcher and outcome assessor were
masked to allocations until study completion.
“ Figure 1 page 409
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes at 12 months: data for 63/64
of intervention group and 60/63 of con-
trol group. Reasons for incomplete out-
come data supplied. Figure 2 page 412
Selective reporting (reporting bias) Low risk There were some modifications from the
protocol but this was additional data col-
lection (clinical outcomes data and knowl-
edge and self report adherence measures).
All data collected were available for this re-
view
Hermann 2011a
Methods Randomised, single-centre, observer masked, parallel-group study
Duration: 4 weeks
Participants Country: Greece
Setting: hospital outpatient clinic
Number of participants: 36
Gender: 11 men, 25 women
Age range: 26 to 76, mean age 55.1 +/- 14
Ethnicity: Caucasian
61% ocular hypertension
Inclusion criteria: age more than 18 years; diagnosis of primary open-angle glaucoma
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Hermann 2011a (Continued)
or ocular hypertension; established topical hypotensive therapy with brimonidine; no
history of ocular surgery in the past 6 months
Exclusion criteria: none
Interventions Open or masked monitoring and brimonidine twice daily or 3 times daily
Outcomes Dosing interval, applications per day, adherence rate, coverage. Assessed using an elec-
tronic monitoring device
Notes Funding sources: not reported. This statement was included in the published paper ”The
authors did not receive support from a for-profit organization.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were then assigned to open or
masked monitoring and to brimonidine BID
or TID using permuted block randomization
and randomization envelopes.” Page e301
Allocation concealment (selection bias) Unclear risk “Patients were then assigned to open or
masked monitoring and to brimonidine BID
or TID using permuted block randomization
and randomization envelopes.” Page e301
Not enough detail about the envelopes re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Subjects received the study medication with
attachedmonitoring devices free of charge and
were familiarizedwith the usage of the bottles.
Patients withmaskedmonitoring were not in-
formed about the electronic adherence mon-
itoring. Instead, these patients were told, the
electronic devices would continuously record
the temperature of the medication. Patients
assigned to open monitoring were fully in-
formed about the monitoring of adherence to
topical therapy.” Page e301
It is not clear if the personnel or participants
were masked
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Subjects received the study medication with
attachedmonitoring devices free of charge and
were familiarizedwith the usage of the bottles.
Patients withmaskedmonitoring were not in-
formed about the electronic adherence mon-
itoring. Instead, these patients were told, the
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Hermann 2011a (Continued)
electronic devices would continuously record
the temperature of the medication. Patients
assigned to open monitoring were fully in-
formed about the monitoring of adherence to
topical therapy.” Page e301
The above statement suggests the partic-
ipants might have been masked, but not
clear as to personnel or outcome assessors.
However, as the outcome measures were
based on electronic recording, lack ofmask-
ing was considered not to be a source of
bias here
Incomplete outcome data (attrition bias)
All outcomes
Low risk 36/37 participants completed the study
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Hermann 2011b
Methods Randomised, single-centre, observer masked, parallel-group study
Duration: 4 weeks
Participants Country: France
Setting: hospital outpatient clinic
Number of participants: 75
Gender: 44 men, 31 women
Age range: 42 to 89 years, mean age 70.0 +/- 11.2 years
Ethnicity: 100% white
Inclusion criteria: 18 years of age or older taking topical therapy for open-angle glaucoma,
chronic angle-closure glaucoma, or ocular hypertension; no history of ocular surgery in
the past 3 months; minimum of 12 months experience with topical glaucoma therapy
Exclusion criteria: none
Interventions Brimonidine twice daily and 3 times daily
Outcomes Electronic monitoring
Dosing interval
Applications per day
Adherence rate %
Coverage %
Medication used per dosing
Drops per dosing
Notes Funding sources: ”The authors did not receive support from a for-profit organization.“
Risk of bias
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Hermann 2011b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Patients were then randomly assigned to
brimonidine bid or tid using permuted
block randomizationwith randomization en-
velopes and received the study medication
with attached monitoring devices free of
charge.“ Page 503
Allocation concealment (selection bias) Low risk ”Patients were then randomly assigned to
brimonidine bid or tid using permuted
block randomizationwith randomization en-
velopes and received the study medication
with attached monitoring devices free of
charge.“ Page 503
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”According to the study protocol electronic ad-
herence monitoring was accomplished in a
masked fashion. Patients were informed about
the electronic monitoring only to the point
that the temperature of the medication would
be recorded.“ Page 502
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”According to the study protocol electronic ad-
herence monitoring was accomplished in a
masked fashion. Patients were informed about
the electronic monitoring only to the point
that the temperature of the medication would
be recorded.“ Page 502
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ”A total of 75 patients [...] were enrolled in
the study; 67 (89%) completed the study and
were included in the statistical analysis. Seven
patients (9.3%) did not complete the study
owing to adverse effects (migraine, dry eye,
redness, allergy). One bottle (1.3%) was not
recollected.“Unclear which group 7 patients
were in. Page 504.
Selective reporting (reporting bias) Unclear risk Difficult to assess with information avail-
able
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I-SIGHT
Methods Randomised, multi-centre, observer masked, parallel-group study
Duration: 12 months
Participants Country: USA
Setting: outpatient clinic
Number of participants: 312
Gender: 195 men, 117 women
Age range: 18 to 80 years, mean age 62.6 years
Study participants were patients with glaucoma considered to non-adherent ”because they
did not take their medication, refill their medication, and/or keep their appointments“
Inclusion criteria: receive treatment for their eye condition at 1 of the 2 participating
eye clinics; be between the ages of 18 and 80 years; be white or black/African American;
have a home or cellular telephone; speak and understand English; be diagnosed with
glaucoma or ocular hypertension for at least 1 year; be prescribed daily doses of topical
glaucoma treatments for at least the past year; not have had eye surgery within the past
3 months; have better than 20/200 vision in at least 1 eye; and be able to read or have
someone who can help them with reading printed materials
Patients also had to acknowledge non-adherence in the past year with medication taking,
obtaining refills or clinic appointments
Interventions Intervention group: 12 telephone calls over 9 months delivered automatically including
tailored information on adherence and glaucoma. The intervention was ”individually
tailored to a participant’s knowledge, attitudes, and behaviors; psychosocial predictors of ad-
herence; health literacy; race and culture; and prescribed medication regimen.“
Control group: usual care
Outcomes Adherence (self report of missed doses)
Prescription refills (pharmacy records)
Appointment keeping
Sources of information: interviews, medical record review, appointment records and
pharmacy data
Notes http://clinicaltrials.gov/ct2/show/NCT00794170
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”After completing the baseline interview, each
participant was randomized into either the
control or intervention group (with a 1:1 ra-
tio). A random number generator was used in
Excel (Microsoft), and participants were ran-
domized in blocks of 10. The sequence was
generated in advance by the research project
manager, and participants were assigned in
the order that they were enrolled. Random-
ization was stratified by clinical site because
of expected differences in sex, race, and edu-
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I-SIGHT (Continued)
cational level between the sites.“ Page E2
Allocation concealment (selection bias) Unclear risk ”Research interviewers were not masked to
assignment because it was necessary to de-
termine treatment group participants’ prefer-
ences for intervention delivery (eg, preferred
telephone number and time of day)“ Page E2
Unclear if this applies to recruitment as well
as outcome assessment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”Adherence data from data abstractions were
coded independently by 2 raters who met in
cases of disagreement to resolve discrepancies“
Page E3
”Research interviewers were not masked to
assignment because it was necessary to de-
termine treatment group participants’ prefer-
ences for intervention delivery (eg, preferred
telephone number and time of day)“ Page E2
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intervention group: 150/157 (96%) inter-
viewed at 12 months
Intervention group: 152/155 (98%) inter-
viewed at 12 months
Figure page E4
Selective reporting (reporting bias) Low risk Investigator confirmed that all outcome
data specified in protocol and collected in
the study were published
Laibovitz 1996
Methods Randomised, single-centre, observer masked, 2-period cross-over study
Duration: 4 weeks
Participants Country: USA
Setting: outpatient clinic
Number of participants: 75
Gender: 36 men, 39 women
Age range: 24 to 88 years, mean age 55.7 years
Ethnicity: white: 29/312 (9.3%), black 283/312 (90.7%)
Inclusion criteria: men and women aged 18 years or older with OAG or OHT who
were clinically suitable for adjunctive therapy. Patients treated with an ophthalmic beta-
blocker for at least 3 weeks prior to randomisation
Exclusion criteria: patients prescribeddorzolamide or pilocarpine in the past, visual acuity
ofworse than20/80 inboth eyes, history or evidence of acute or chronicACG, insufficient
pupillary dilation for an adequate retinal examination, history or presence of uveitis
or retinal detachment. Patients with asthma or chronic obstructive pulmonary disease,
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Laibovitz 1996 (Continued)
clinically significant renal disease, severe physical disability or any contraindication to
the use of dorzolamide, timolol or pilocarpine ophthalmic solution
Interventions Group A: 2% dorzolamide 3 times daily during period 1 and 2% pilocarpine 4 times
daily during period 2
Group B: 2% pilocarpine 4 times daily during period 1 and 2% dorzolamide 3 times
daily during period 2
Both groups continued to receive 0.5% timolol twice daily throughout the study
Follow-up: short-term; 14 days per period
Outcomes Adherence assessed through self report via interviewer-administered questionnaire using
previously validated tool (COMTol). Patients were asked how often they missed eye
drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always
Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients
asked whether quality of life was interfered with by side effects or activity limitations.
Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely
IOP reduction assessed with Goldmann applanation tonometer
Visual field defects assessed with Humphrey Field Analyser 24-2 programme
Notes Funding Sources: Sponsored by Merck & Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generator
used
Allocation concealment (selection bias) Low risk Central allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Because one purpose of our study was to de-
termine patient preference between the two
ophthalmic medications, and dosing regimen
is an integral part of such preference, we delib-
erately did not mask the treatment regimens
to the patients or study physician. However,
the interviewer administering the COMTol
questionnaire was masked to the patient’s reg-
imen, interviews were conducted in a brightly
lit room (to induce miosis in all patients), and
patients were instructed not to disclose their
dosing frequency to the interviewer.” Page
823
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Because one purpose of our study was to de-
termine patient preference between the two
ophthalmic medications, and dosing regimen
is an integral part of such preference, we delib-
erately did not mask the treatment regimens
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Laibovitz 1996 (Continued)
to the patients or study physician. However,
the interviewer administering the COMTol
questionnaire was masked to the patient’s reg-
imen, interviews were conducted in a brightly
lit room (to induce miosis in all patients), and
patients were instructed not to disclose their
dosing frequency to the interviewer.” Page
823
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ”Of the 75 patients who entered the study, 51
completed both treatment periods (Table III)
. A total of 21 patients discontinued therapy
due to adverse experiences while receiving pi-
locarpine (12 from group A and 9 from group
B), whereas only 2 patients discontinued ther-
apy due to adverse experiences while receiving
dorzolamide (both from group B).[...] Only
1 patient, who was lost to follow-up during
the first period, discontinued dorzolamide
and did not enter the second period.“ Page
825
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Laster 1996
Methods Randomised, single-centre, 2-period cross-over study
Duration: 60 days
Participants Country: USA
Setting: university-based glaucoma clinic
Number of participants: 13
Gender: 2 men, 11 women
Age range and mean age: data unavailable
Ethnicity: data unavailable
Inclusion criteria: patients diagnosed with OAG who were prescribed pilocarpine solu-
tion 4 times a day
Exclusion criteria: not stated
Interventions Group 1: pre-weighed bottle of pilocarpine of appropriate concentration (according to
prescription) in a medication vial fitted with the Prescript TimeCap in period 1 and pre-
weighed bottle of pilocarpine of appropriate concentration (according to prescription)
without the vial or cap in period 2
Group 2: pre-weighed bottle of pilocarpine of appropriate concentration (according to
prescription) without the vial or cap in period 1 and pre-weighed bottle of pilocarpine
of appropriate concentration (according to prescription) in a medication vial fitted with
the TimeCap in period 2
Follow-up: short-term; 30 days per period
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Laster 1996 (Continued)
Outcomes Adherence assessed by weighing the drop bottle at the end of each 30-day period and
also through self report via a patient questionnaire completed at the end of each period
Notes Funding sources: non-commercially funded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Drawing of lots (each participant was ran-
domly given a number using a statistical ta-
ble then numbers were drawn to assign to
either group 1 or group 2)
Allocation concealment (selection bias) High risk Open random allocation schedule used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
masked
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors were not masked. The
effects may vary with outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 13 patients were [..] able to com-
plete the study” Page 655
This suggests that more people could have
been enrolled and not reported
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Muir 2012
Methods Randomised, single-centre, parallel-group study
Duration: 6 months
Participants Country: USA
Setting: medical centre
Number of participants: 127 (131 enrolled, 4 withdrew)
Gender: 126 men, 1 woman
Age range 43 to 87 years; mean age: 66 years (SD 9.6)
Ethnicity: 29% white, 80% African American, 1% other
Inclusion criteria: score of 18 or higher on Mini Mental State Examination patients
diagnosed with OAG who were prescribed pilocarpine solution 4 times a day
Exclusion criteria: best-corrected visual acuity in the better seeing eye < 20/200; eye
surgery in the past month
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Muir 2012 (Continued)
Interventions Educational intervention lasting 20 minutes (one-on-one session) including ”informa-
tional video“. Language of video varied according to participants’ tested health literacy
level
Standard care
Outcomes Number of days without medication
Medication possession ratio
Self reported disease knowledge
Satisfaction with care
Notes Funding sources: non-commercially funded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Subjects were randomized in a one-to-one
fashion to standard care or an educational
intervention.“ Page 161
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 131 enrolled, 4 withdrew, no other infor-
mation on follow-up
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Nakakura 2012
Methods Randomised, multi-centre, parallel-group study
Duration: 12 weeks
Participants Country: Japan
Setting: hospital
Number of participants: 36 (39 enrolled, 3 withdrew)
Gender: 19 men, 17 women
Average age: 71 years
Ethnicity: not reported, assumed Japanese
Inclusion criteria: primary open-angle glaucoma; exhibition of a stable intraocular pres-
sure for more than 3 months; no history of fixed-combination therapy; treated with
3 antiglaucoma eye drops (various preparations of prostaglandin F2-alpha analogues +
beta-blockers + carbonic anhydrase inhibitors)
Exclusion criteria: congenital or narrow-angle glaucoma; ocular surgery including laser
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Nakakura 2012 (Continued)
surgery within the previous 6 months; any previous glaucoma surgery; ocular inflam-
mation, neovascular glaucoma or steroid-induced glaucoma; any other conditions that
prevent use of the Goldmann applanation tonometer; at risk of visual acuity and visual
fields worsening during this study; allergy to preservatives
Interventions Latanoprost 0.005%/timolol 0.5% plus brinzolamide 1%
Dorzolamide 1%/timolol 0.5% plus latanoprost 0.005%
Outcomes Intraocular pressure
Questionnaire including question ”How often do you forget administration per week?“
Adverse effects
If both eyes included, right eye analysed
Notes Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20/21 participants in latanoprost/timolol
plus brinzolamide group followed up com-
pared to 16/18 in dorzolamide/timolol plus
latanoprost
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Norell 1979
Methods Randomised, single-centre, 2-period, parallel-group study. Randomisation stratified by
age
Duration: 40 days
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Norell 1979 (Continued)
Participants Country: Sweden
Setting: hospital outpatient clinic
Number of participants: 73 (82 recruited, 9 excluded from analysis)
Gender: 45 men, 37 women
Age range: 50 to 90 years, median age 73 years
Ethnicity: not stated
Inclusion criteria: patients with chronic simple glaucoma, glaucomatous visual field
defect, cupping of optic disc, raised IOP and prescribed pilocarpine eye drops 3 times a
day in an eye with visual acuity of least 2/60
Exclusion criteria: not stated
Interventions Experimental group: no intervention for the first 20-day monitoring period, then 30-
minute education and tailoring programme implemented at clinic appointment and
monitoring continued for a further 20 days. Education involved basic information on
glaucoma and its treatment, supplied by a tape-slide show and leaflet. Patients’ knowledge
and understanding was then checked by ophthalmology assistant and insufficiently mas-
tered information re-emphasised. Patients were encouraged to ask questions and discuss
problems with medication. Tailoring involved patient interview with an ophthalmology
assistant to ascertain daily routine and to advise on best times to instil eye drops within
daily routine. Advice given re: storage of drops. Times and drop routine written for each
patient
Control group: monitoring for 2 x 20-day periods, no intervention
Follow-up: short-term; 20 days per period
Outcomes Adherence to therapy assessed with a medication monitor which recorded the date and
hour each time the medication bottle was opened
Notes Funding sources: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “They were stratified for age and randomly
allocated to an experimental group or a con-
trol group.” Page 1031
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients were not told the purpose of themon-
itor until we had finished collecting all the
data.” Page 1032
Electronic outcomemonitoring considered
at low risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk 73/82 (89%) participants provided com-
plete data
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Norell 1979 (Continued)
“The second monitor record was lost in nine
cases-one patient suffered acute heart disease,
two were admitted to hospital for long-term
care, in two cases the monitor was lost or bro-
ken, and in four no record was obtained be-
cause themonitor battery was defective.“Page
1032
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Okeke 2009
Methods Randomised, 2-centre, 2-period, parallel-group study
Duration: 3 months
Participants Country: USA
Setting: Glaucoma Services of the Wilmer Eye Institute and the Scheie Eye Institute
Number of participants: 66
Gender:3 6 men, 30 women
Age range: mean age 66.1 in intervention group; 63.8 in the control group
Ethnicity: 40 black, 25 white, 1 Asian
Inclusion criteria: people with glaucoma being treated with a prostaglandin analogue in
1 or both eyes
Exclusion criteria: people were excluded if they were unable to understand the study,
they did not put in their own drops, or they could not use the dosing aid
Interventions The intervention consisted of the following:
• 10-minute educational video
• structured discussion
• reminder telephone calls
• activation of the audible and visible alarms on the dosing aid
People in the control group received usual care, i.e. were told that it is important to take
their eye drops as prescribed but had no other intervention
Outcomes Adherence rate as measured by a dosing aid device and a questionnaire
Intraocular pressure
Notes Funding sources: supported in part by theNational Institutes of Health, charitable grants
and Alcon
http://clinicaltrials.gov/ct2/show/NCT00333463
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”To perform the randomization procedure, a
string of random numbers was selected from
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a random numbers table....“ Page 2287
Allocation concealment (selection bias) Low risk ”...The numbers were placed into envelopes
and then sealed and initialed across the seal.
The envelopes were numbered consecutively
starting with 1. When an eligible patient was
identified, an envelope was opened; if the en-
velope contained an even number then the
participant received the intervention.“ Page
2287
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking was not described and interven-
tion/control group received very different
interventions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All 66 patients randomisedwere apparently
assessed for adherence at 3 months, how-
ever the following statement implies there
were some dropouts in the intervention
group. ”For the 35 patients randomized to
the intervention group, telephone calls were
made at weeks 1 to 5, 7, 9, and 11. The num-
ber of patients contacted was highest at week
1 (100%), and over the remaining weeks
there was a decline in the number success-
fully contacted (week 11, 63%). Reasons for
the decline included early dropout from study,
inability to contact patients, and early final
visit.“ Page 2289
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Ring 2011
Methods Quasi-experimental, single-centre study
Duration: 3 months
Participants Country: UK
Setting: hospital outpatient clinic
Number of participants: 124 (127 recruited, 2 withdrew and 1 died)
Gender: 47 men, 77 women
Age range: 40 to over 80, mean age = 71 years (calculated from frequencies on table 5,
page 32), median age 73 years
Ethnicity: 101 white, 12 Asian, 8 black, 3 other
Inclusion criteria: people diagnosed with open-angle glaucoma, ocular hypertension,
normal tension glaucoma on ocular hypotensive drops
Exclusion criteria: people who were unable to understand and sign and informed consent
form, people who could not see the film clearly
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Interventions Educational intervention: specially developed film
Outcomes Questionnaire
Weight of eye drop bottles
Notes Funding Sources: International Glaucoma Association
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The participants were randomly allocated to
either the control group or the intervention
group. The allocation can be referred to as
random because the film was shown on var-
ious days and no prior knowledge of when
the participants were attending their routine
clinic appointment was known.” Page 27
Further information from investigator:
”The participants were allocated into each
group purely by attending an outpatient ap-
pointment on different days. The control or
test intervention was set for different days and
the participants arrived according to their
outpatient appointment. This was considered
random allocation as the student researcher
had no influence over which participant ar-
rived on which day.“
Allocation concealment (selection bias) High risk Information from investigator:
”The person recruiting the participants was
the student researcher as outlined in the dis-
sertation. This person was aware of which
group the participant was allocated to.“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 127 participants were enrolled into
the study over a four week period; 2 partici-
pants withdrew without a specific reason and
1 participant died before the 3 month data
was collected. All results are based on a co-
hort of responding participants (n=124). 110
participants completed the study (88.7%). 14
of the original cohort did not respond to the
3 month postal questionnaire (non-response
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rate of 11.3%).” Page 32
Selective reporting (reporting bias) Low risk Investigator confirmed all data collected
were reported
Sakai 2005
Methods Quasi-randomised, single-centre, parallel-group study
Duration: 12 weeks
Participants Country: Japan
Setting: university-based ophthalmology clinic
Number of participants: 36 (40 recruited, 2 withdrew after randomisation, 2 excluded
after washout period as IOP < 20 mmHg and, therefore, no longer met criteria)
Gender: 14 men, 22 women
Age range: 45 to 75 years, mean age 64 years
Ethnicity: Asian 100%
Inclusion criteria: patients with primary ACG diagnosed by indentation gonioscopy
and UBM, existence of synechial angle closure, released pupillary block by LPI at least
3 months before the study and a history of elevated IOP > 21 mmHg without any
treatment with antiglaucoma medications
Exclusion criteria: previous ocular surgery other than LPI, acute PAC, use of oral ac-
etazolamide because of poor IOP control, suspected secondary angle closure related to
uveal effusion, uveitis, lens subtractions or trauma. Patients who were already scheduled
for surgery that would affect IOP such as trabeculectomy or phacoemulsification. Pa-
tients prescribed medicines for hypertension, cardiovascular disease, bronchial asthma
and allergy to any of the study medication
Interventions Latanoprost (L) group: monotherapy with latanoprost once daily
Timolol/dorzolamide (T/D) group: unfixed combination therapy with 0.5% timolol
maleate twice daily and 1% dorzolamide 3 times daily
Follow-up: short-term; 12 weeks
Outcomes Adherence assessed though self report via patient questionnaire at 12 weeks. Patients were
asked how many times they had forgotten to apply their drops. Pre-defined responses
were; less than once a week, once a week, 2 or 3 times a week and 4 or more times a week
IOP reduction assessed with Goldmann applanation tonometer
Visual field defects assessed with Humphrey Field Analyser, automated perimetry full-
threshold 30-2 programme
Notes Funding sources: none
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk “All but 1 of the remaining 36 patients were
randomly allocated to ...”
Page 484
Assigned by rotation. 1 patient not ran-
domised but assigned to latanoprost group
to minimise possible side effects of timolol
administration due to a pulse rate of 59/
min at first evaluation
Allocation concealment (selection bias) High risk Open random allocation schedule used
”One patient was assigned.. to the latanoprost
group to eliminate the risk of side effects.“
Correspondence with investigator: ”It was
open labelled and allocation schedule was not
concealed prior to the assignment to the sub-
jects. Two subjects were dropped out by their
own will, may be because of the allocation.“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Difficult to mask participants as dosing fre-
quency differed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Correspondence with investigator: ”It was
open labelled, and the number of the eye drop
(s) was different.“
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data available for 4 patients; 2o with-
drew after randomisation and 2 were ex-
cluded after washout period
Attrition rate: 10%
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Schenker 1999
Methods Randomised, multi-centre, 2-period, cross-over study
Duration: 12 weeks
Participants Country: USA
Setting: hospital outpatient clinic
Number of participants: 202
Gender: 77 men, 125 women
Mean age: 59.4 years
Ethnicity: white 142 (70%), black 47 (23%), Hispanic 13 (6%)
Inclusion criteria: patients with a diagnosis of OAG or OHT. IOP ≥ 22 mmHg in at
least 1 eye after a 3-week washout period
Exclusion criteria: contact lens use within 3 weeks of study start, a history of acute
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or chronic ACG, occludable angles, a history of recent ocular inflammation or foreign
body, a history of uveitis, concomitant use of systemic medications known to affect IOP,
contraindications to beta-blockers and existing renal disease
Interventions Group A: timolol gel once daily during period 1 followed by timolol solution twice daily
during period 2
Group B: timolol solution twice daily during period 1 followed by timolol gel once daily
during period 2
Follow-up: short-term; 6 weeks per period
Outcomes Adherence assessed through self report via interviewer-administered questionnaire. Pa-
tients were asked how often they missed 1 or 2 doses of test medication during the last
2 weeks. Pre-defined responses were scored on a scale of 1 to 5: never = 1, rarely = 2,
occasionally = 3, frequently = 4, always = 5
IOP reduction assessed with Goldmann applanation tonometer
Notes Funding sources: sponsored by Merck & Co.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “... were enrolled in this 12-week, random-
ized observer-masked, two-period cross-over
study.” Page 138
“This was an open-label, multicenter,
randomized, observer-masked, two-period
crossover study ...“ Page 139
Correspondence with investigators: ”Sub-
jects were randomized 1:1 to one of two se-
quences of treatment (tgel/ts or ts/tgel); ran-
domization done within each center in blocks
of 4.“
Allocation concealment (selection bias) Low risk Correspondence with investigators: ”Allo-
cation completed by use of sealed envelopes
opened at the time of enrollment“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and care providers deliberately
not masked. Difficult to mask participants
as dosing frequencies were different
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A member of the clinic staff who was masked
to the treatment the patient was receiving ad-
ministered an anti-glaucoma patient-prefer-
ence questionnaire.” Page 139
Correspondence with investigators: ”Inves-
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tigator office staff was blinded until after the
analysis was reported.“
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10 patients did not complete both periods,
a further 8 patients were excluded from the
questionnaire analysis because of other pro-
tocol violations. Attrition rate: 9%. A fur-
ther 4 patients (11%) did not respond to
the adherence question
99/102 group A and 93/100 group B com-
pleted the study. Reasons for non-comple-
tion described well and summarised here:
Adverse event: n = 5, 4 probably related to
medication, 1 unrelated
Other reason: 3 lost to follow-up, 1 with-
drew consent, 1 for personal reasons
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Sheppard 2003
Methods Randomised, single-centre, parallel-group study
Duration: 3 months
Participants Country: UK
Setting: hospital outpatient clinic
Number of participants: 73 (92 recruited, 19 withdrew)
Gender: not stated
Mean age 73 years (SD 11.6)
Ethnicity: not stated
Inclusion criteria: patients with a diagnosis of long-term chronic stable glaucoma
Exclusion criteria: no telephone access, difficulties using the phone, diagnosis of cognitive
impairment
Interventions Intervention: glaucoma monitoring nurse-led clinic involving consultations of 15 min-
utes duration divided into 2 parts. The first part was a standard assessment designed to
monitor and record health details, such as current health status and recent ocular history.
Eye examinations included visual acuity, visual field test and IOP test using Goldmann’s
applanation tonometry. The second part was a semi-structure educational session tai-
lored to individual patient needs
Control: general ophthalmic clinic involving consultations of 10minutes duration which
included the standard assessment, a fundus examination and remainder of time utilised
according to each individual clinician
Outcomes Adherence assessed through self report patient questionnaire during a structured tele-
phone interview
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Notes Funding sources: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients who consented to take part were
allocated [...] using a computerised randomi-
sation table“. Page 17
Allocation concealment (selection bias) Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 92participants: 36/42 (86%)nurse-led and
37/50 (74%) doctor clinic
“There was no difference in age, length of
time diagnosed with glaucoma or the ques-
tionnaire measures between the participants
who dropped out and those who remained in
the study.” Page 18
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
Sverrisson 1999 Europe
Methods Randomised, multi-centre, observer masked, 2-period, cross-over study
Duration: 38 days
Participants Countries: 8 sites in 5 European countries: Belgium, Denmark, Iceland, Sweden and
Switzerland
Setting: outpatient clinics
Number of participants: 93
Gender: 35 men, 58 women
Age range: 44 to 87 years, mean age: 69.5
Ethnicity: white 92 (98.9%), other 1 (1.1%)
Inclusion criteria: patients 18+ years with a diagnosis of OAG or OHT in both eyes.
IOP of ≥ 22 mmHg 2 hrs after the morning dose of timolol maleate on study day 1
after run-in
Exclusion criteria: patients previously treated with dorzolamide or pilocarpine. Visual
acuity of worse than 20/80 in both eyes, evidence of ACG, current use of contact lenses,
intraocular surgery or significant trauma within 6 months or intraocular laser surgery
within 3 months of initiation of the study, history or presence of retinal detachment or
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other conditions for which pilocarpine might be appropriate. Asthma, chronic obstruc-
tive pulmonary disease, renal disease, severe physical disabilities or any contraindications
to the use of pilocarpine, dorzolamide or timolol ophthalmic solutions
Interventions Group A: 2% dorzolamide/0.5% timolol combination twice daily during period 1 and
2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 2
Group B: 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 1
and 2% dorzolamide/0.5% timolol combination twice daily during period 2
Follow-up: short-term; 14 days per period
Outcomes Adherence assessed through self report via interviewer-administered questionnaire using
previously validated tool (COMTol). Patients were asked how often they missed their
drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always
Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients
asked whether quality of life was interfered with by side effects or activity limitations.
Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely
IOP reduction assessed with Goldman applanation tonometer
Visual field defects assessed with Humphrey Field Analyser at all US sites and some
European sites. The other European sites used an Octopus perimeter
Notes Funding sources: sponsored by Merck & Co.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generator
used
Allocation concealment (selection bias) Low risk Central allocation used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because the purpose of the studies was to de-
termine patient preference between two ther-
apeutic regimes and dose regimen is an in-
tegral part of such preference, the treatment
regimens were deliberately not masked to the
patients or the study physician. However, the
interviewer administering the COMTol ques-
tionnaire was masked to the patient’s regimen,
interviews were conducted in a brightly lit
room (to induce miosis in all patients), and
patients were instructed not to disclose their
dose frequency to the interviewer.” Page 823
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Because the purpose of the studies was to de-
termine patient preference between two ther-
apeutic regimes and dose regimen is an in-
tegral part of such preference, the treatment
regimens were deliberately not masked to the
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patients or the study physician. However, the
interviewer administering the COMTol ques-
tionnaire was masked to the patient’s regimen,
interviews were conducted in a brightly lit
room (to induce miosis in all patients), and
patients were instructed not to disclose their
dose frequency to the interviewer.” Page 823
Incomplete outcome data (attrition bias)
All outcomes
High risk Insufficient information to permit judge-
ment. Difficult to assess attrition rate from
paper and following contact with author.
18 patients (19%) were excluded from the
adherence analysis, 19 (20%) from qual-
ity of life analysis concerning side effects
and 22 (24%) from quality of life analysis
concerning activity limitations. Numbers
of patients involved in IOP and visual field
test analysis were not published and could
not be obtained from authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Sverrisson 1999 USA
Methods Randomised, multi-centre, observer masked, 2-period cross-over study
Duration: 38 days
Participants Countries: USA (10 sites)
Setting: outpatient clinics
Number of participants: 97
Gender: 41 men, 56 women
Age range: 27 to 83 years, mean age 60.4 years
Ethnicity: white 70 (72.2%), black 18 (18.6%), other 9 (9.3%)
Inclusion criteria: patients 18+ years with a diagnosis of OAG or OHT in both eyes.
IOP of ≥ 22 mmHg 2 hours after the morning dose of timolol maleate on study day 1
after run-in
Exclusion criteria: patients previously treated with dorzolamide or pilocarpine. Visual
acuity of worse than 20/80 in both eyes, evidence of ACG, current use of contact lenses,
intraocular surgery or significant trauma within 6 months or intraocular laser surgery
within 3 months of initiation of the study, history or presence of retinal detachment or
other conditions for which pilocarpine might be appropriate. Asthma, chronic obstruc-
tive pulmonary disease, renal disease, severe physical disabilities or any contraindications
to the use of pilocarpine, dorzolamide or timolol ophthalmic solutions
Interventions Group A: 2% dorzolamide/0.5% timolol combination twice daily during period 1 and
2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 2
Group B: 2% pilocarpine 4 times daily plus 0.5% timolol twice daily during period 1
and 2% dorzolamide/0.5% timolol combination twice daily during period 2
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Follow-up: short-term; 14 days per period
Outcomes Adherence assessed through self report via interviewer-administered questionnaire using
previously validated tool (COMTol). Patients were asked how often they missed their
drops. Responses were marked on a scale of 0 to 6: 0 = never, 6 = always
Quality of life assessed via interviewer-administered questionnaire (COMTol). Patients
asked whether quality of life was interfered with by side effects or activity limitations.
Responses were marked on a scale of 0 to 5: 0 = not at all, 5 = extremely
IOP reduction assessed with Goldman applanation tonometer
Visual field defects assessed with Humphrey Field Analyser at all US sites and some
European sites. The other European sites used an Octopus perimeter
Notes Funding sources: sponsored by Merck & Co.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generator
used (contact with trialists)
“[...] patients who met the inclusion criteria
and who had none of the exclusion criteria on
study day 1 were randomly assigned to group
A or group B.” Page 316
Allocation concealment (selection bias) Low risk Central allocation used (contact with trial-
ists)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because the purpose of the studies was to de-
termine patient preference between two ther-
apeutic regimes and dose regimen is an in-
tegral part of such preference, the treatment
regimens were deliberately not masked to the
patients or the study physician. However, the
interviewer administering the COMTol ques-
tionnaire was masked to the patient’s regimen,
interviews were conducted in a brightly lit
room (to induce miosis in all patients), and
patients were instructed not to disclose their
dose frequency to the interviewer.” Page 823
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Because the purpose of the studies was to de-
termine patient preference between two ther-
apeutic regimes and dose regimen is an in-
tegral part of such preference, the treatment
regimens were deliberately not masked to the
patients or the study physician. However, the
interviewer administering the COMTol ques-
tionnaire was masked to the patient’s regimen,
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interviews were conducted in a brightly lit
room (to induce miosis in all patients), and
patients were instructed not to disclose their
dose frequency to the interviewer.” Page 823
Incomplete outcome data (attrition bias)
All outcomes
High risk Insufficient information to permit judge-
ment. Difficult to assess attrition rate from
paper and following contact with author.
12 patients (13%) were excluded from the
adherence analysis, 8 (8%) from the qual-
ity of life analysis concerning side effects
and 9 (9%) from the quality of life anal-
ysis concerning activity limitations. Num-
bers of patients involved in IOP and visual
field test analysis were not published and
could not be obtained from authors
See table 5. Lower follow-up in timolol
plus pilocarpine group (63%) compared to
combination group (97%), however, in in-
ternational study good follow-up, 95% and
92%, in both groups
Selective reporting (reporting bias) Unclear risk Difficult to judge without access to proto-
col; no immediate cause for concern
ACG: angle closure glaucoma
COMTol: Comparison of Ophthalmic Medications for Tolerability
IOP: intraocular pressure
LPI: laser peripheral iridotomy
OAG: open-angle glaucoma
OHT: ocular hypertension
SD: standard deviation
UBM: ultrasound biomicroscopy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akafo 1995 Did not measure adherence
Amon 1990 Not a randomised study
Bayer 2004 Not a randomised study, adherence not measured
Bhojwani 1981 Not a randomised study, adherence not measured
55Interventions for improving adherence to ocular hypotensive therapy (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Blair 2001 Not a randomised study
Blair 2004 Not a randomised study
Bron 2004 Measured adherence but did not publish results. Author contacted and gave reason, ”such an evaluation of
compliance is not reliable“.
Chang 1991 Not a randomised study
Derick 1992 Adherence not measured
Dunker 2007 Not a randomised study
Flowers 2006 Single-arm study
Ghinato 1996 Unclear whether participants were randomised to 1 of 2 groups. No reply from author
Goni 2005 Did not measure adherence
Granstrom 1982 Not a randomised study
Gulkilik 2011 Did not measure adherence
Hasegawa 2005 Not a randomised study
Hughes 2005 Did not measure adherence
Hunter 1999 Very little information available, no paper, no other evidence of study found. Several attempts made to
contact author without success
Inoue 2011 Not a controlled trial
Inoue 2012 Not a controlled trial
Kass 1987 Not a randomised study
Klein 2003 Not a randomised study, adherence not measured
Konstas 2001 Did not measure adherence
Kurtz 2004 Did not measure adherence
Lorenz 2011 Did not measure adherence
March 2000 Did not measure adherence
NCT00230763 Non-randomised study
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NCT00262626 Non-randomised study
NCT00328835 Non-randomised study not assessing adherence
NCT00329095 Non-randomised study
NCT00348062 Non-randomised study
NCT01415401 Non-randomised
Novack 1988 Did not measure adherence
Rolle 2012 Not a controlled trial
Rossi 2011 Not a controlled trial
Sanchez-Pulgarin 2011 Not a controlled trial
Sclar 1991 Not a randomised study, adherence not measured
Shibuya 2003 Adherence measured although the 2 types of drops being compared were instilled with the same dosage
frequency of once daily
Wandel 1986 Not a randomised study, adherence not measured
Yie 2000 Not a randomised study, adherence not measured
Characteristics of ongoing studies [ordered by study ID]
ISRCTN25754048
Trial name or title Glaucoma compliance aids research project
Methods Randomised, single-centre, parallel-group study
Participants Country: UK
Setting: hospital outpatient clinic
Target number of participants: 100
Inclusion criteria: patients with a diagnosis of OAG, using anti-glaucoma eye drops, able to instil drops
independently
Exclusion criteria: patients prescribed more than 1 eye drop, patients with other eye problems, patients unable
to give informed consent, patients < 40 years
Interventions Intervention group: adherence aid and usual care which involves glaucoma assessment followed by assessment
for appropriate adherence aid with instruction on how to use it; patients also continue to receive the usual
care normally provided within the outpatients department
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Control group: glaucoma assessment and usual care normally provided within the outpatients department
Outcomes Adherence to therapy assessed through self report via patient questionnaire
Starting date September 2006
Contact information See trial register entry
Notes http://www.controlled-trials.com/ISRCTN25754048
ISRCTN31673586
Trial name or title Comparing the after-use sensation and safety of long acting (LA) carteolol 2 % versus timolol LA 0.5 % in
simple intra-ocular hypertension and glaucoma
Methods Randomised controlled trial, parallel-group
Participants People with unilateral or bilateral ocular hypertension or primary open-angle glaucoma and intra-ocular
pressure controlled with beta-blocker monotherapy: pressure < 21mmHg and visual field stable
Interventions Carteolol long-acting 2%: daily, 1 drop at 8 am in the eye(s) to be treated over 3 months
Timolol long-acting 0.5%: daily, 1 drop at 8 am in the eye(s) to be treated over 3 months
Outcomes Compliance, reported at 1 and 3 months was one of the secondary outcomes for this study
Starting date December 2007
Contact information See trial register entry
Notes http://www.controlled-trials.com/ISRCTN31673586
ISRCTN89683704
Trial name or title Helping adherence with glaucoma treatment
Methods Randomised, single-centre, parallel-group study
Duration: 2 years
Participants Country: UK
Setting: hospital outpatient clinic
Target number of patients: 200
Inclusion criteria: newly diagnosed or previously untreated glaucoma patients (using established standard
criteria as documented in the European Glaucoma Society Guidelines), prescribed travoprost only, male or
female, > 18 years of age
Exclusion criteria: those who cannot speak English fluently (to eliminate any potential bias by poor inter-
pretation of information by a translator), those whose drops will be applied by care home staff/carers/home-
helpers
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Interventions Intervention group: the intervention group will spend time with a Glaucoma Support Assistant (GSA) who
will discuss/provide general aspects relating to glaucoma and anti-glaucomatous therapy, advice and practical
help with drop application techniques, advice on taking eye drops within their own schedule/routine and an
invitation for the participant to ask any questions about anything they are unsure of. In addition, patients
will be asked to discuss their normal routine and a mutually agreeable time and place will be decided upon
for patients to administer their drops. Patients will be advised to take their drops before a given point in their
routine, to leave their drops where this ”event“ normally happens (e.g. by their toothbrush holder). A helpline
number will also be given so that participants or their carers can call the on-call GSA at any time during
clinic hours for additional information about glaucoma and drop application. The initial intervention group
appointment is expected to last about 30 minutes
Standard care group/control group: the control group will receive information in the form of our expected
standard care and a leaflet about glaucoma with their ophthalmologist. Expected standard care consists of a
brief explanation about glaucoma and the degree to which the particular patient has the condition, a summary
of the proposed future management for that patient, including how frequently and when drop administration
should be carried out and the importance of the condition with respect to driving and future vision. In
addition, they will receive a contact telephone number for the glaucoma research unit in case of any problems
with the electronic device or adverse events
Follow-up: 32 weeks
Outcomes Patient adherence, measured by an electronic dosing monitor to give a % adherence and persistence score
Self perception of adherence will be measured using self rating questionnaires
Level of knowledge about glaucoma will be measured using self rating questionnaires
The individual components of the intervention will be assessed using questionnaires so as to identify which
components are in most demand for a given population
A cost-effectiveness approach will determine the additional cost associated with the additional benefits. In
this way, the ’fixed’ (staff, overheads etc) and ’variable’ costs of the intervention protocol will be estimated per
patient. Resource utilisation and variance by individual patient will be monitored prospectively.
Social demographic and medical history data recorded will be used in the socio-economic and health analyses
Starting date November 2009
Contact information See trial register entry
Notes http://www.controlled-trials.com/ISRCTN89683704
NCT00376974
Trial name or title The effect of education on patient compliance
Methods Randomised controlled trial, parallel-group
Participants People with glaucoma attending for routine examination
Interventions Educational video
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Outcomes Intraocular pressure
Score on glaucoma educational test
Starting date March 2005
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00376974
NCT00454922
Trial name or title Effect of glaucoma educators on adherence to prescribed therapeutic regimens in glaucoma patients
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: prevention
Participants 100
Interventions Education versus standard care
Outcomes Primary outcome measures: primary outcome is adherence (time frame: 6 months)
Secondary outcome measures: differences between patients randomised to standard of care and education
intervention (time frame: 6 months)
Differences between dropouts and non-dropouts (time frame: 6 months)
Starting date From clinical trals.gov
Start date: October 2007; end date: May 2008
From contact with investigators December 2011
”Our study evaluating the “Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in
Glaucoma Patients” (http://clinicaltrials.gov/show/NCT00454922) just started a few months ago and is still re-
cruiting participants. We won’t have outcomes to report for another 12-18 months.“
Contact information See trial register entry
Notes http://clinicaltrials.gov/show/NCT00454922
NCT00465803
Trial name or title Compliance study comparing DuoTrav to TRAVATAN plus timolol using the dosing aid
Methods Randomised controlled trial, parallel-group
Participants People with open-angle glaucoma or ocular hypertension
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NCT00465803 (Continued)
Interventions DuoTrav
Travatan/timolol
Outcomes Patient compliance
Starting date March 2007
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00465803
NCT00508469
Trial name or title Adherence assessment with Travalert dosing aid
Methods Parallel-group randomised controlled trial
Participants People diagnosed with glaucoma or ocular hypertension
Interventions Dosing aid device
Outcomes From ClinicalTrials.gov
Primary outcome measures: the primary objective is to compare patients adherence using Travalert® device
in the different treatment groups (time frame: use) (designated as safety issue: no)
Secondary outcome measures: safety and satisfaction (time frame: use) (designated as safety issue: no)
Starting date July 2007
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00508469
NCT00573638
Trial name or title Effects of Xal-Ease on patient compliance with Xalatan
Methods Intervention model: single group assignment
Masking: open label
Primary purpose: treatment
Participants 50
Interventions Device: Xal-Ease device to be used with Xalatan eye drops
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NCT00573638 (Continued)
Outcomes Primary outcome measures: the primary outcome measure is compliance with the medication Xalatan using
and not using the Xal-Ease delivery aid for their glaucoma treatment (time frame: 6 months)
Secondary outcome measures: to determine if any of the other factors mentioned in the survey affect com-
pliance to their medical regimen (time frame: 6 months)
To see whether or not the Xal-Ease device helps patients conserve medication, i.e. - aids in drops not distilled
in the eye (time frame: 6 months)
Starting date February 2005
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00573638
NCT00626067
Trial name or title Study of patient use and perception of the Travatan dosing aid
Pilot study of patient acceptance and impact of the new Travatan™ compliance monitoring dispenser (Tra-
vatan™ dosing aid)
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: single group assignment (but has 3 interventions)
Masking: double-blind (subject, investigator)
Primary purpose: supportive care
Participants 45
Interventions Travatan compliance monitoring dispenser
Fully functioning, partially functioning and non-functioning
Outcomes From clinicatrials.gov
Primary outcomemeasures: assess patients’ opinions regarding newTravatan compliancemonitoring dispenser
(time frame: 6 weeks) (designated as safety issue: no)
Secondary outcome measures: pilot study of the impact of physician monitoring of compliance on patient
compliance (time frame: 6 weeks) (designated as safety issue: no)
Starting date September 2006
Investigator indicates manuscript in preparation
Contact information See trial register entry
Notes http://clinicaltrials.gov/show/NCT00626067
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NCT00676637
Trial name or title GAS - Glaucoma Adherence Study
Methods Allocation: non-randomised
Intervention model: single group assignment
Masking: open-label
Participants 100
Interventions TravAlert dosing aid
Outcomes Mean change from baseline in intraocular pressure at 4 months
Starting date May 2008
Contact information See trial register entry
Notes http://clinicaltrials.gov/show/NCT00676637%20%C2%A0
NCT00756184
Trial name or title 1-year randomized control trial investigating the value of an intervention to enhance adherence in glaucoma
patients receiving prostaglandin monotherapy and in patients who are candidates for adjunctive therapy
Methods Parallel-group randomised controlled trial
Participants People with newly diagnosed open-angle glaucoma, or ocular hypertensive subjects naive to medical therapy
and people who have failed monotherapy with any prostaglandin analogue
Interventions Intensive glaucoma adherence and education during the course of 1 year compared to intensive, equal-time
eye care education without any direct adherence or glaucoma specific education
Outcomes Adherence rate (% of days patient used the medication) as monitored by a dosing aid electronic device,
intraocular pressure (morning) and persistency to therapy
Follow-up time: 1, 3, 6, 9 and 12 months
Starting date September 2007
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00756184
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NCT00767793
Trial name or title A multi-center, double-masked, randomized, placebo-controlled, ascending dose study of INS117548 oph-
thalmic solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma
Methods Randomised controlled trial, parallel-group
Participants People with primary open-angle glaucoma or ocular hypertension
Interventions INS117548 at various concentrations
Placebo
Outcomes Include compliance and rate of discontinuation
Starting date September 2008
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00767793
NCT00887029
Trial name or title A 12 week comparison of DuoTrav and Xalacom at 24 hours post-dose in the treatment of open-angle
glaucoma (the DVX study)
Methods Randomised controlled trial, cross-over
Participants People with primary open-angle glaucoma or ocular hypertension
Interventions DuoTrav
Xalacom
Outcomes Intraocular pressure
Compliance and patient preference
Starting date January 2009
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT00887029
NCT01125306
Trial name or title Efficiency of Xal-Ease device in glaucoma and/or ocular hypertension (OHT) patients, treated with Xalatan
or Xalacom
Methods Intervention model: single group assignment
Masking: open-label
Primary purpose: supportive care
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NCT01125306 (Continued)
Participants 50
Interventions Device: Xal-Ease
Outcomes Primary outcome measures: consumption of Xalatan/Xalacom bottles per year per patient (time frame: 12
months)
Secondary outcome measures: evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease (time
frame: 12 months)
Characterising the optimal conditions for proper usage of the Xal-Ease device (time frame: 12 months)
Starting date June 2009
Contact information See trial register entry
Notes http://clinicaltrials.gov/ct2/show/NCT01125306
NCT01409421
Trial name or title Research protocol: glaucoma treatment adherence and persistence
Methods Parallel-group randomised controlled trial
Participants People with glaucoma
Interventions Motivational interviewing, reminder calls and standard care
Outcomes From ClinicalTrials.gov
Primary outcome measures: MEMS-based medication adherence and persistence (time frame: 1 month)
(designated as safety issue: no) comparing adherence and persistence between the intervention and control
groups. Medication Event Monitoring Systems record the date and time a pill bottle is opened, evaluating
the percentage of prescribed doses taken during one-week intervals, but will augment it by also considering a
more fine-grained percentage of prescribed doses taken in required dosing window (defined as within 3 hours
before or after the scheduled time) as a second primary outcome measure.
Secondary outcome measures: counsellor-rated medication adherence (time frame: 1 month) (designated as
safety issue: no). Will supplement MEMS-based adherence metrics with a counsellor rating of adherence
completed by the glaucoma educator during each in-person or telephone contact with intervention group
participants. The interview also measures patients’ perceived reasons for non-adherence, including treatment
cost, lack of commitment based on low perceived benefits of treatment and fear of potential adverse drug
events (ADEs)
Starting date April 2011
Contact information See trial register entry
Notes http://clinicaltrials.gov/show/NCT01409421
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NCT01417689
Trial name or title Eyedrop Instillation Technique
Methods Parallel-group randomised controlled trial
Participants People with glaucoma or suspected glaucoma
Interventions Standard eye drop instillation compared to experimental technique of eye drop instillation
Outcomes From ClinicalTrials.gov
Primary outcome measures: complete success (time frame: day 1, immediately after intervention) (designated
as safety issue: no). Total success is defined as: patient manages to instil 1 eye drop into the eye spending only
1 eye drop. Difference in the proportion of patients achieving successful eye drop instillation in each of the
2 groups. For the main analysis the results of the first eye (right or left randomly determined will be used) a
mixed model with both eyes in the analysis will also be presented for sensitivity analysis.
Secondary outcome measures: qualified success (time frame: day 1, same day as intervention) (designated as
safety issue: no). Qualified success is defined as: patient manages to instil 1 eye drop into the eye regardless of
the amount of drops spent. Difference in the proportion of patients achieving successful eye drop instillation
in each of the 2 groups. For the main analysis the results of the first eye (right or left randomly determined
will be used) a mixed model with both eyes in the analysis will also be presented for sensitivity analysis.
Number of drops (time frame: day 1) (designated as safety issue: no). Number of eye drops spent on attempted
instillation in the first eye (randomly assigned). The average number of drops spent on each of the groups
will be compared. Mixed models with data from both eyes will also be presented for sensitivity analysis
Starting date August 2011
Contact information See trial register entry
Notes http://clinicaltrials.gov/show/NCT01417689
OAG: open-angle glaucoma
OHT: ocular hypertension
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Study design, interventions and outcomes in included studies
Study RCT type Intervention Control group Length of fol-
low-up
Main outcome
measures
Comments
1 Gray 2011 Parallel-group Educa-
tion and tailor-
ing programme
Usual care 12 months and
24 months
Adherence (pre-
scription
data and ques-
tionnaire)
Persistence (pre-
scription and
dispensing data)
Intraocular
pressure
Patient knowl-
edge
-
2 Hermann 2011 Parallel-group,
factorial
Brimonidine
twice daily
Masked moni-
toring
Brimonidine 3
times daily
Open monitor-
ing
1 month Adher-
ence (electronic
monitoring de-
vice)
-
3 Herman 2011a Parallel-group Brimonidine
twice daily
Brimonidine 3
times daily
4 weeks Adher-
ence (electronic
monitoring)
-
4 I-SIGHT Parallel-group Telephone au-
tomated educa-
tion and tailor-
ing programme
Usual care 12 months Adherence (self
report of missed
doses)
Prescription re-
fills (pharmacy
records)
Appointment
keeping
Sources of in-
forma-
tion: interviews,
medical record
review, appoint-
ment records,
and pharmacy
data
-
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Table 1. Study design, interventions and outcomes in included studies (Continued)
5 Laibovitz 1996 Cross-over 2% dor-
zolamide three
times daily
2% pilocarpine
four times daily
during period 1
14 days per pe-
riod
Adherence
(questionnaire -
COMTol)
Persis-
tence (number
of patients who
continued treat-
ment)
Quality of life
(questionnaire -
COMTol)
Intraocular
pressure (Gold-
mann applana-
tion tonometer)
Vi-
sual field defects
(Humphrey
Field Analyser)
Both groups
continued to re-
ceive 0.5% tim-
olol twice daily
throughout the
study
6 Laster 1996 Cross-over Pre-weighed
bottle of
pilocarpine in a
medication vial
fitted with the
Prescript Time-
Cap
Pre-weighed
bottle of
pilocarpine in a
medication vial
fitted with the
TimeCap
30 days per pe-
riod
Adher-
ence (weighing
the drop bot-
tle and ques-
tionnaire)
-
7 Muir 2012 Parallel-group Educational in-
tervention last-
ing 20 minutes
(one-on-
one session) in-
cluding ”infor-
mational
video“ delivered
at varying liter-
acy levels
Standard care 6 months Ad-
herence (num-
ber of dayswith-
out medication)
Self
reported disease
knowledge
Satisfaction
with care
Language of
video varied ac-
cording to par-
ticipants’
tested health lit-
eracy level
8 Nakakura 2012 Parallel-group Latanoprost 0.
005%/timolol
0.5% plus brin-
zolamide 1%
Dorzo-
lamide 1%/tim-
olol 0.5%
plus latanoprost
0.005%
12 weeks Intraocular
pressure
Adherence (self
reported)
-
9 Norell 1979 Parallel-group Educa-
tion and tailor-
ing programme
No intervention 20 days Ad-
herence (medi-
cation monitor)
-
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Table 1. Study design, interventions and outcomes in included studies (Continued)
10 Okeke 2009 Parallel-group Educa-
tion and tailor-
ing programme
No intervention 3 months Adherence rate
(dosing aid de-
vice)
Intraocular
pressure
-
12 Ring 2011 Quasi-
experimental
Educational in-
tervention
(film)
No intervention 3 months Adherence (re-
turn of bottles)
Patient knowl-
edge (question-
naire)
-
12 Sakai 2005 Quasi-
experimental
Latanoprost
once daily
0.5%
timolol maleate
twice daily and
1% dorzo-
lamide 3 times
daily
3 months Adherence
(questionnaire)
Intraocular
pressure (Gold-
mann applana-
tion tonometer)
Vi-
sual field defects
(Humphrey
Field Analyser)
-
13 Schenker 1999 Cross-over Timolol gel
once daily
Timolol solu-
tion twice daily
6 weeks per pe-
riod
Adherence
(questionnaire)
Intraocular
pressure (Gold-
mann applana-
tion tonometer)
-
14 Sheppard 2003 Parallel-group Education and
tailoring
Usual care 3 months Adherence
(questionnaire)
Patient knowl-
edge (question-
naire)
-
15 Sverrisson 1999
Europe
Cross-over 2%
dorzolamide/0.
5% timo-
lol combination
twice daily
2% pilocarpine
four times daily
plus 0.5% timo-
lol twice daily
14 days per pe-
riod
Adher-
ence (question-
naire COMTol)
Per-
sistence (num-
ber of patients
who completed
treatment)
Quality of life
(questionnaire
-
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Table 1. Study design, interventions and outcomes in included studies (Continued)
COMTol)
Intraocular
pressure (Gold-
man applana-
tion tonometer)
Vi-
sual field defects
(Humphrey
Field
Analyser/ Octo-
pus perimeter)
16 Sverrisson USA Cross-over 2%
dorzolamide/0.
5% timo-
lol combination
twice daily
2% pilocarpine
4 times daily
plus 0.5% timo-
lol twice daily
14 days per pe-
riod
Adher-
ence (question-
naire COMTol)
Per-
sistence (num-
ber of patients
who completed
treatment)
Quality of life
(questionnaire
COMTol)
Intraocular
pressure (Gold-
man applana-
tion tonometer)
Vi-
sual field defects
(Humphrey
Field Analyser)
-
COMTol: Comparison of Ophthalmic Medications for Tolerability
Table 2. Effect of education and tailoring on adherence
Study Outcome
measure
Follow-up
period
Outcome
measure vari-
able type
Intervention
n/N (%)
or
mean (SD)
Control
n/N(%)
or
mean (SD)
Reported P
value
Comments
Gray 2011 Number
of people who
were adherent
12 months Dichotomous 45/64 (70%) 27/63 (43%) 0.002 Data
from page 185
of Gray PhD
thesis
“Refill ad-
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Table 2. Effect of education and tailoring on adherence (Continued)
herence” mea-
sured by con-
tacting GPs
and pharma-
cists for pre-
scrip-
tion and dis-
pensing infor-
mation during
the 1-year fol-
low-up. Peo-
ple
who collected
100% of pre-
scrip-
tions were de-
fined as adher-
ent
I-SIGHT Self
reported med-
ication adher-
ence: number
of people not
reporting
missing drops
in 1 month
”last visit“
which could
be 6, 9 or 12
months
Dichotomous 30.2% 27.0% ”treatment
x visit“ inter-
action 0.18
Also reported
a number
of other mea-
sures of adher-
ence (see ta-
ble 3, page E5)
including self
reported refill
adherence, self
reported ap-
pointment ad-
herence, chart
report medi-
cation adher-
ence, chart re-
port refill ad-
herence, chart
report ap-
pointment ad-
herence,
none of which
showed statis-
tically sig-
nificant differ-
ences between
groups
Muir 2012 Days without
medication
6 months Continuous 63 (198) n =
67
65 (198) n =
60
0.955 (calcu-
lated from
data t-test)
-
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Table 2. Effect of education and tailoring on adherence (Continued)
Norell 1979 % of time ex-
ceeding 8-
hour dose in-
tervals
% (number of
missed doses)
20 days Dichotomous
(denominator
not reported)
13%
6% (120)
24%
15% (338)
< 0.001 Table page
1032
Measured us-
ing a medica-
tion monitor
Unit of anal-
ysis not same
as unit of ran-
domisation
Re-
ported P value
tests differ-
ence in change
between
first time pe-
riod (be-
fore interven-
tion) and sec-
ond time pe-
riod (after in-
tervention)
Okeke 2011 Adherence
rate
Change be-
tween pre-in-
tervention
3 months and
post-
intervention 3
months
3 months Continuous
Continuous
0.73 (0.22)
0.19 (0.20)
0.51 (0.30)
0.06 (0.30)
0.001
0.01
Table 3 page
2289
Adherence
rate measured
usingTravatan
dosing aid de-
vice
*Ring 2011 Number
of people who
were adherent
3 months Dichotomous 18/54 (33.3) 19/56 (33.9) 0.947 (calcu-
lated from
data)
Page 44 of
RingMSc the-
sis
People who re-
turned bottles
within 10% of
target weight
were defined
as adherent
Sheppard
2003
Adherence 3 months Continuous “No differences were found between the two groups
on adherence using an ANCOVA with the pre-ap-
pointment score as a covariate”
Page 19
Adher-
ence measured
by question-
naire using an
11-point
72Interventions for improving adherence to ocular hypotensive therapy (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Effect of education and tailoring on adherence (Continued)
response scale:
0 “I never use
my eye drops”
to 10 “I always
use
my eye drops”.
Reported as a
contin-
uous variable
in the paper
but only pre-
appointment
mean (SD)
reported. Also
reported “sig-
nificantly fewer
of the [inter-
vention] group
reported
[specific prob-
lems with ad-
herence] com-
pared to [con-
trol group].”
Adherence: taking medicine as prescribed
See text for description of education and tailoring packages in each study.
*Ring 2011 did not include any tailoring.
Table 3. Effect of drug regimen on adherence
Study Outcome
measure
Follow-up
period
Outcome
measure vari-
able type
Intervention*
n/N (%)
or
mean (SD)
Control
n/N(%)
or
mean (SD)
Reported P
value
Comments
Hermann
2011
Adherence
rate (%)
4 weeks Continuous 73.3 (13)
n = 18
64.0 (12)
n = 18
0.02 Table 3 page
e302
Adher-
ence rate de-
fined as “Ratio
of recorded dos-
ing events to in-
tended dosing
events
for the observed
time period.”A
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Table 3. Effect of drug regimen on adherence (Continued)
recorded dos-
ing event was
application of
1 or more
drops within
30 min-
utes following
the first appli-
cation
Herman
2011a
Adherence
rate (%)
4 weeks Continuous 72.2 (19)
n = 33
62.1 (16)
n = 34
0.04 Text pages 504
and 505
Adher-
ence rate de-
fined as for
Herman 2011
above
Laibovitz
1996
Reported
missed doses
4 weeks Continuous 0.8 (SE 0.18) 2.3 (SE 0.18) < 0.001 COMTol
questionnaire:
“How often did
you miss one
or more doses?
” Graded 0
(never) to 6
(always). Data
are from cross-
over study but
data from
2 time periods
appear to have
been pooled
Nakakura
2012
Forgot admin-
istration
12 weeks Dichotomous 2/19 2/16 0.855 (calcu-
lated)
Ques-
tion ”How of-
ten do you for-
get administra-
tion per week?“
Never/
within 2 times
per week/
more than 3
times per week
Sakai 2005 Reported
missed doses
3 months Dichotomous 16/18 (88.9) 13/18 (72.2) 0.207 (calcu-
lated)
“How
many times pa-
tient has forgot-
ten to apply the
eye drop?” An-
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Table 3. Effect of drug regimen on adherence (Continued)
swer less than
once a week
defined as ad-
herent
Schenker
1999
Reported
never missed
dose
3 months Dichotomous 141/180 (78.
3)
123/182 (67.
6)
0.021 (calcu-
lated)
Table V Page
144
Frequency of
missed doses:
never, rarely,
occasionally,
frequently, al-
ways
Analysis
ignores cross-
over design
Sverrisson
1999 Europe
Reported
missed doses
14 days Continuous 0.1 (0.1) 1.4 (0.1) - COMTol
questionnaire:
“How often did
you miss one
or more doses?
” Graded 0
(never) to 6
(always). Data
are from cross-
over study but
data from 2
time pe-
riods appears
to have been
pooled
Sverrisson
1999 USA
Reported
missed doses
14 days Continuous 0.2 (0.1) 1.2 (0.1) -
COMTol: Comparison of Ophthalmic Medications for Tolerability
SE: standard error
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Glaucoma
#2 MeSH descriptor Ocular Hypertension
#3 MeSH descriptor Intraocular Pressure
#4 glaucoma*
#5 (intraocular or intra ocular) next pressure*
#6 ocular hypertensi*
#7 IOP or OHT
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Antihypertensive Agents
#10 antihypertensi*
#11 therap* or treat* or medicat* or drug* or drop*
#12 (#9 OR #10 OR #11)
#13 MeSH descriptor Attitude to Health
#14 MeSH descriptor Patient Compliance
#15 MeSH descriptor Patient Dropouts
#16 MeSH descriptor Treatment Refusal
#17 MeSH descriptor Patient Acceptance of Health Care
#18 MeSH descriptor Patient Satisfaction
#19 adhere* or non adhere* or complian* or non complian* or concordance or persistence or acceptance or coperat* or co operat* or
conform*
#20 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (treat*)
#21 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (medic*)
#22 (discontinu* or abstention or abstain* or stop* or abandon*) near/4 (therap*)
#23 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24 (#8 AND #12 AND #23)
Appendix 2. MEDLINE (OvidSP) search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp glaucoma/
14 exp ocular hypertension/
15 exp intraocular pressure/
16 glaucom$.tw.
17 ((intraocular or intra ocular) adj1 pressure$).tw.
18 ocular hypertensi$.tw.
19 (IOP or OHT).tw.
20 or/13-19
21 exp antihypertensive agents/
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22 antihypertensi$.tw.
23 (therap$ or treat$ or medicat$ or drug$ or drop$).tw.
24 or/21-23
25 exp attitude to health/
26 exp patient compliance/
27 exp patient dropouts/
28 exp treatment refusal/
29 exp patient acceptance of health care/
30 exp patient satisfaction/
31 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or
conform$).tw.
32 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw.
33 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw.
34 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw.
35 or/25-34
36 20 and 24 and 35
37 12 and 36
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
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32 11 or 24 or 31
33 exp glaucoma/
34 exp intraocular hypertension/
35 exp intraocular pressure/
36 glaucom$.tw.
37 ((intraocular or intra ocular) adj1 pressure$).tw.
38 ocular hypertensi$.tw.
39 (IOP or OHT).tw.
40 or/33-39
41 exp antihypertensive agent/
42 antihypertensi$.tw. (28653)
43 (therap$ or treat$ or medicat$ or drug$ or drop$).tw.
44 or/41-43
45 exp attitude to health/
46 exp patient compliance/
47 exp patient/
48 exp treatment refusal/
49 exp patient attitude/
50 exp patient satisfaction/
51 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or
conform$).tw.
52 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw.
53 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw.
54 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw.
55 or/45-54
56 40 and 44 and 55
57 32 and 56
Appendix 4. CINAHL (EBSCO) search strategy
1 Randomized Controlled Trial.pt.
2 Controlled Clinical.pt.
3 Randomized Controlled Trials.sh.
4 Random Allocation.sh.
5 Double Blind Method.sh.
6 Single Blind Method.sh.
7 1 or 2 or 3 or 4 or 5 or 6
8 (Animals not Human).sh.
9 7 not 8
10 Clinical Trial.pt.
11 exp Clinical Trials/
12 (clin$ adj25 trial$).ti,ab.
13 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
14 placebos.sh.
15 Placebo$.ti,ab.
16 random$.ti,ab.
17 Research Design.sh.
18 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19 18 not 8
20 19 not 9
21 Comparative Study.sh.
22 exp Evaluation studies/
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23 Follow Up Studies.sh.
24 Prospectice Studies.sh.
25 (control$ or prospective$ or volunteer$).ti,ab.
26 21 or 22 or 23 or 24 or 25
27 26 not 8
28 27 not (9 or 20)
29 9 or 20 or 28
30 exp GLAUCOMA/ or exp OCULAR HYPERTENSION/
31 exp INTRAOCULAR PRESSURE/
32 glaucoma$.mp.
33 (ocular adj1 hypertension).mp.
34 (intraocular adj1 pressur$).mp.
35 OHT.mp.
36 30 or 31 or 32 or 33 or 34 or 35
37 exp ATTITUDE TO HEALTH/ or exp PATIENT COMPLIANCE/ or exp TREATMENT REFUSAL/
38 exp PATIENT CARE PLANNING/ or exp PATIENT EDUCATION/
39 ((patient$ or user$) adj3 (acceptance or complian$ or non-complian$ or concordance or persisten$ or adher$ or non-adhere$ or
co?operat$ or non-co?operat$ or conform$)).mp.
40 ((discontinu$ or abstention or abstain or stop$ or abandon$) adj3 (treatment$ or medication$ or medicine$ or therap$)).mp.
41 37 or 38 or 39 or 40
42 (therap$ or medicine$ or medication$ or treatment$ or drug$ or drop$).mp.
43 29 and 36 and 41 and 42
Appendix 5. PsycINFO and PsycEXTRA (OvidSP) search strategy
1 exp glaucoma/
2 glaucom$.tw.
3 ((intraocular or intra ocular) adj1 pressure$).tw.
4 ocular hypertensi$.tw.
5 (IOP or OHT).tw.
6 or/1-5
7 exp antihypertensive drugs/
8 antihypertensi$.tw.
9 (therap$ or treat$ or medicat$ or drug$ or drop$).tw.
10 or/7-9
11 exp compliance/
12 exp treatment compliance/
13 exp treatment dropouts/
14 exp treatment refusal/
15 exp health behavior/
16 exp health attitudes/
17 exp client attitudes/
18 exp Client Satisfaction/
19 (adhere$ or non adhere$ or complian$ or non complian$ or concordance or persistence or acceptance or coperat$ or co operat$ or
conform$).tw.
20 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 treat$).tw.
21 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 medic$).tw.
22 ((discontinu$ or abstention or abstain$ or stop$ or abandon$) adj4 therap$).tw.
23 or/11-22
24 6 and 10 and 23
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Appendix 6. Web of Science search strategy
Topic=(glaucoma* or ocular hypertension or IOP or OHT) AND Topic=(therap* or treat* or medic* or drug* or drop*) AND Topic=
(adhere* or complian* or concordance)
Appendix 7. ZETOC search strategy
”glaucoma adherence“
Appendix 8. OpenGrey search strategy
Glaucoma AND (Adherence OR Compliance OR Concordance)
Appendix 9. metaRegister of Controlled Trials search strategy
(Adherence OR Compliance OR Concordance) AND Glaucoma
Appendix 10. ClinicalTrials.gov search strategy
(Adherence OR Compliance OR Concordance) AND Glaucoma
Appendix 11. ICTRP search strategy
Glaucoma = Condition AND Adherence OR Compliance OR Concordance = Intervention
Appendix 12. Questions on patient knowledge
The following questions were used in Ring 2011. The participants were required to answer true/false.
1. Glaucoma is a disease that affects the eyes and no other parts of the body
2. Glaucoma is always painful
3. Raised eye pressure can cause glaucoma
4. Treatment for glaucoma is life long
5. The most common treatment for glaucoma is surgery
6. Eye drops have side effects that affect other parts of the body
7. Most people have symptoms that warn them that glaucoma is getting worse
8. Glaucoma affects the central part of your vision before the sides
9. Regular check-ups are not necessary
10. Lowering the eye pressure reduces the risk of sight loss in glaucoma
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WH A T ’ S N E W
Last assessed as up-to-date: 26 June 2012.
Date Event Description
28 June 2012 New search has been performed Issue 4 2013: New searches have been conducted. One new
co-author, Jennifer Evans, has joined the review team for the
update
28 June 2012 New citation required and conclusions have changed Issue 4 2013: Eight new trials have been included.
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 2, 2009
Date Event Description
1 September 2009 Amended Issue 1, 2010: ’Results of the search’ amended as the number of trials stated to be eligible for
inclusion in the review was incorrect. Eleven trials were relevant for the review; three ongoing and
eight completed
5 June 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
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Co-ordinating the review: TG, JE
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Organising retrieval of papers: TG
Screening retrieved papers against inclusion criteria: TG, HG, DH, RH, HW, JE
Appraising quality of papers: TG, HW, DH, RH, JE
Extracting data from papers: TG, HW, DH, RH, JE
Writing to authors of papers for additional information: TG, JE
Obtaining and screening data on unpublished studies: TG
Data management for the review: TG, JE
Entering data into RevMan: TG, JE
81Interventions for improving adherence to ocular hypotensive therapy (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis of data: TG, JE
Interpretation of data: TG, JE
Writing the review: TG, JE
Securing funding for the review: DH, HW
D E C L A R A T I O N S O F I N T E R E S T
The authors of this review (with the exception of Jennifer Evans) were involved in one included study (Gray 2011).
S O U R C E S O F S U P P O R T
Internal sources
• University of Manchester, UK.
External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The Cochrane Collaboration’s new tool for assessing the risk of bias has been used in updates of this review. In the update in 2012, two
new outcomes were added: patient’s knowledge about glaucoma and costs.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Medication Adherence; Ocular Hypertension [∗drug therapy]; Ophthalmic Solutions [administration & dosage]; Patient Education
as Topic; Randomized Controlled Trials as Topic; Reminder Systems [instrumentation]
MeSH check words
Humans
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